~~Table of Contents~~GELESIS HOLDINGS, INC.

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF ~~CASH FLOWS~~

~~(UNAUDITED)~~NONCONTROLLING INTEREST, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share and per share data)

For the period

from February

14, 2020

Nine months

(Inception)

ended September 30,

through September 30,


2021

2020
Cash Flows from Operating Activities:



Net loss

$
(3,657,398)

$
(114,691)
Adjustments to reconcile net loss to net cash used in operating activities:

Interest earned on marketable securities held in Trust Account

(142,997)

(96,143)
Unrealized gain on marketable securities held in Trust Account

(2,231)

(41,496)
Transaction costs associated with the Initial Public Offering

0

671,901
Change in fair value of warrant liabilities

2,284,340

(613,900)
Deferred tax provision

0

8,714
Changes in operating assets and liabilities:

Prepaid expenses

26,157

(81,365)
Accounts payable and accrued expenses

1,129,240

54,771
Net cash used in operating activities

(362,889)

(212,209)

Cash Flows from Investing Activities:

Cash withdrawn from Trust Account to pay for franchise taxes

176,006

0
Investment of cash into Trust Account

0

(276,000,000)
Net cash provided by (used in) investing activities

176,006

(276,000,000)



Cash Flows from Financing Activities:



Proceeds from issuance of Class B common stock to Sponsor

0

25,000
Proceeds from sale of Units, net of underwriting discounts paid

0

270,480,000
Proceeds from sale of Private Placement Warrants

0

7,520,000
Proceeds from promissory note - related party

0

150,000
Repayment of promissory note - related party

0

(150,000)
Payment of offering costs

0

(671,828)
Net cash provided by financing activities

0

277,353,172



Net Change in Cash

(186,883)

1,140,963
Cash - Beginning of period

491,827

0
Cash - End of period

$
304,944

$
1,140,963
Non-Cash investing and financing activities:

Initial classification of Class A common stock subject to possible redemption

$
0

$
276,000,000
Change in value of Class A common stock subject to possible redemption

$
(4,772)

$
87,639
Deferred underwriting fee payable

$
0

$
9,660,000


	Noncontrolling Interest			Redeemable Convertible Preferred Stock						Common Stock				Additional Paid-in Capital			Accumulated Other Comprehensive Income			Accumulated Deficit			Total Stockholders' Equity (Deficit)
				Shares			Amount			Shares		Amount
Balance at December 31, 2020	$	12,429			18,446,525		$	213,211			2,155,490	$	1	$	23,907		$	938		$	(171,784	)	$	(146,938	)
Retroactive application of recapitalization		—			29,367,421			—			3,431,604		—		—			—			—			—
Adjusted Balance at December 31, 2020	$	12,429			47,813,946		$	213,211			5,587,094	$	1	$	23,907		$	938		$	(171,784	)	$	(146,938	)
Accretion of senior preferred stock to redemption value		—			—			33,761			—		—		(33,761	)		—			—			(33,761	)
Exercise of Series A-3 warrants		—			617,390			2,997			—		—		—			—			—			—
Stock based compensation expense		—			—			—			—		—		1,455			—			—			1,455
Exercise of share-based awards		—			—			—			2,634		—		4			—			—			4
Accretion of noncontrolling interest put option to redemption value		94			—			—			—		—		—			—			(94	)		(94	)
Foreign currency translation adjustment		(546	)		—			—			—		—		—			(411	)		—			(411	)
Net loss		—			—			—			—		—		—			—			(18,586	)		(18,586	)
Balance at March 31, 2021	$	11,977			48,431,336		$	249,969			5,589,728	$	2	$	(8,395	)	$	527		$	(190,464	)	$	(198,331	)

Balance at December 31, 2021	$	11,855			18,736,936		$	311,594			2,410,552	$	1	$	(64,549	)	$	219		$	(265,507	)	$	(329,836	)
Retroactive application of recapitalization		—			29,829,719			—			3,837,640		—		—			—			—			—
Adjusted Balance at December 31, 2021	$	11,855			48,566,655		$	311,594			6,248,192	$	1	$	(64,549	)	$	219		$	(265,507	)	$	(329,836	)
Accretion of Legacy Gelesis senior preferred stock to redemption value prior to Business Combination		—			—			37,934			—		—		(37,934	)		—			—			(37,934	)
Conversion of Legacy Gelesis convertible preferred stock into common stock upon Business Combination		—			(48,566,655	)		(349,528	)		48,566,655		—		349,528			—			—			349,528
Proceeds from Business Combination, net of issuance costs and assumed liabilities (Note 3)		—			—			—			17,399,440		6		70,472			—			—			70,478
Conversion of Legacy Gelesis preferred stock warrants into common stock warrants upon Business Combination		—			—			—			—		—		16,747			—			—			16,747
Recognition of earnout liability upon Business Combination		—			—			—			—		—		(58,871	)		—			—			(58,871	)
Assumed private placement warrant liability upon Business Combination		—			—			—			—		—		(8,140	)		—			—			(8,140	)
Stock based compensation expense		—			—			—			—		—		13,989			—			—			13,989
Exercise of warrants		—			—			—			176,126		—		4			—			—			4
Accretion of noncontrolling interest put option to redemption value		88			—			—			—		—		—			—			(88	)		(88	)
Foreign currency translation adjustment		(239	)		—			—			—		—		—			(137	)		—			(137	)
Net loss		—			—			—			—		—		—			—			(5,703	)		(5,703	)
Balance at March 31, 2022	$	11,704			—			—			72,390,413	$	7	$	281,246		$	82		$	(271,298	)	$	10,037

The accompanying notes are an integral part of ~~the~~these unaudited condensed consolidated financial statements.

~~Table~~

GELESIS HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)


	Three Months Ended March 31,
	2022			2021
Cash flows from operating activities:
Net loss	$	(5,703	)	$	(18,586	)
Adjustments to reconcile net loss to net cash used in operating activities:				.
Amortization of intangible assets		567			567
Reduction in carrying amount of right-of-use assets		132			41
Depreciation		1,019			174
Stock-based compensation		13,989			1,455
Unrealized loss on foreign currency transactions		65			143
Noncash interest expense		40			19
Accretion on marketable securities		—			(1	)
Change in the fair value of earnout liability		(33,869	)		—
Change in the fair value of warrants		(3,484	)		2,074
Change in the fair value of convertible promissory notes		156			—
Change in fair value of One S.r.l. call option		258			48
Changes in operating assets and liabilities:
Account receivables		(1,177	)		(169	)
Grants receivable		(198	)		(1,273	)
Prepaid expenses and other current assets		(2,010	)		318
Inventories		(2,888	)		846
Other assets		—			(1,222	)
Accounts payable		3,502			(1,192	)
Accrued expenses and other current liabilities		528			200
Operating lease liabilities		(134	)		(37	)
Deferred income		(5,550	)		8,459
Other long-term liabilities		(426	)		(158	)
Net cash used in operating activities		(35,183	)		(8,294	)
Cash flows from investing activities:
Purchases of property and equipment		(1,963	)		(6,354	)
Maturities of marketable securities		—			24,000
Net cash (used in) provided by investing activities		(1,963	)		17,646
Cash flows from financing activities:
Proceeds from Business Combination, net of transaction costs		70,478			—
Principal repayment of notes payable		(418	)		(186	)
Repayment of convertible promissory notes due to related party, held at fair value		(27,284	)		—
Proceeds from issuance of promissory notes (net of issuance costs of $0 and $30, respectively)		—			3,506
Proceeds from the exercise of warrants		4			10
Proceeds from exercise of share-based awards		—			4
Net cash provided by financing activities		42,780			3,334
Effect of exchange rates on cash		(46	)		(973	)
Net increase in cash		5,588			11,713
Cash and cash equivalents at beginning of year		28,397			48,144
Cash and cash equivalents at end of period	$	33,985		$	59,857
Noncash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expense	$	1,721		$	889
Recognition of earnout liability	$	58,871			—
Recognition of private placement warrant liability	$	8,140			—
Supplemental cash flow information:
Interest paid on notes payable	$	95		$	43

The accompanying notes are an integral part of ~~Contents~~these unaudited condensed consolidated financial statements.

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~5

GELESIS HOLDINGS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER 30, 2021~~(In thousands, except share and per share data)

Nature of the Business and Basis of Presentation

Nature of Business

~~(Unaudited)~~

~~NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS~~

Gelesis Holdings, Inc., or the Company, formerly known as Capstar Special Purpose Acquisition Corp. ~~(the “Company”)~~or “CPSR”, is a ~~blank check~~commercial stage biotherapeutics company incorporated ~~in Delaware on February 14, 2020.~~under the laws of the State of Delaware. The Company aims to transform weight management through proprietary biomimetic hydrogel technology, inspired by the compositional and mechanical properties of raw vegetables. Since its inception, the Company has devoted substantially all of its efforts to business planning, licensing technology, research and development, commercial activities, recruiting management and technical staff and raising capital and has financed its operations through the issuance of redeemable convertible preferred and common stock, a license and collaboration agreement, supply and distribution agreements, long-term loans, convertible bridge note financings, and government grants.

The Company currently manufactures and markets its first product, Plenity® (the “Product”), which is based on a proprietary hydrogel technology. Plenity® received de novo clearance from the FDA on April 12, 2019 as a Class II medical device to aid in weight management in adults with excess weight or obesity, Body Mass Index (BMI) of 25 to 40 kg/m2, when used in conjunction with diet and exercise. In June 2019, the Company received approval to market Plenity in Europe through a Conformité Européenne (CE) mark for Plenity as a class III medical device indicated for weight loss in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m2, when used in conjunction with diet and exercise. Plenity, which is available by prescription in the United States, became available for first commercial sale in May 2020 to a limited number of consumers. In October 2020, availability was ~~formed~~increased to test commercial interest and consumer experience. Activities associated with a full commercial launch of Plenity in the United States began in late 2021, and in February 2022, the Company launched the first national broad awareness media campaign for the ~~purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination~~product.

On July 19, 2021, Gelesis, Inc. (together with ~~1 or more businesses (the “Business Combination”~~its consolidated subsidiaries, “Legacy Gelesis”).

~~Although the Company is not limited to a particular industry or geographic region for purposes of consummating~~ entered into a Business Combination Agreement (“Business Combination Agreement”) with CPSR, a special purpose acquisition company. On January 13, 2022, CPSR, a Delaware corporation and the ~~Company intends~~predecessor company consummated the previously announced business combination (“Business Combination”), pursuant to ~~focus on businesses in~~ the ~~consumer, healthcare and technology, media and telecommunications (“TMT”) industries. The Company is an early stage and emerging growth company and, as such, the Company is subject to all~~terms of the ~~risks associated with early stage~~Business Combination Agreement, dated as of July 19, 2021 (as amended on November 8, 2021 and ~~emerging growth companies.~~

~~The Company has one wholly-owned subsidiary,~~December 30, 2021), by and among CPSR, CPSR Gelesis Merger Sub, Inc., ~~which was incorporated in the State of Delaware on July 2, 2021 (“Merger Sub”).~~

As of September 30, 2021, the Company had not commenced any operations. All activity through September 30, 2021 relates to the Company’s formation, its initial public offering (“Initial Public Offering”), which is described below, the search for a target company for a Business Combination and activities in connection with the proposed business combination with Gelesis, Inc., a Delaware corporation and wholly-owned subsidiary of CPSR (“~~Gelesis”~~Merger Sub”) ~~(see Note 7)~~, and Legacy Gelesis. Pursuant to the Business Combination Agreement, on the closing date, (i) Merger Sub merged with and into Legacy Gelesis (the “Merger”), with Legacy Gelesis as the surviving company in the Merger, and, after giving effect to such Merger, Legacy Gelesis became a wholly-owned subsidiary of CPSR and (ii) CPSR changed its name to “Gelesis Holdings, Inc.” (together with its consolidated subsidiaries, “Gelesis Holdings”). The ~~Company will not generate any operating revenues until after the completion of its initial~~ Business Combination, ~~at the earliest. The Company generates non-operating income in the form of interest income from the marketable securities held in the Trust Account.~~

The registration statement for the Company’s Initial Public Offering was declared effective on July 1, 2020. On July 7, 2020, the Company consummated the Initial Public Offering of 27,600,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), which includes the full exercise by the underwriters of the over-allotment option to purchase an additional 3,600,000 Units, at $10.00 per Unit, generating gross proceeds of $276,000,000, which is described in Note 4.

~~Simultaneously~~together with the closing of the Initial Public Offering, the Company consummated the sale of 7,520,000 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to Capstar Sponsor Group, LLC (the “Sponsor”), generating gross proceeds of $7,520,000, which is described in Note 5.

~~Transaction costs amounted to $15,851,828, consisting of $5,520,000 of underwriting fees, $9,660,000 of deferred underwriting fees and $671,828 of other offering costs.~~

~~Following the closing of the Initial Public Offering on July 7, 2020, an amount of $276,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering~~PIPE financing and the sale of the ~~Private Placement Warrants~~backstop purchase shares, generated approximately $105 million in gross proceeds and $70.5 million in net proceeds (See Note 3). On January 14, 2022, Gelesis Holdings’ securities began trading on the New York Stock Exchange under the symbols “GLS” and “GLS.W”.

The Business Combination was ~~placed~~accounted for as a reverse recapitalization in ~~a trust account (the “Trust Account”). The proceeds are held in the Trust Account located~~conformity with accounting principles generally accepted in the United ~~States and shall be invested only in U.S. government securities, within~~States. Under this method of accounting, CPSR has been treated as the ~~meaning set forth in Section 2(a)(16)~~"acquired" company for financial reporting purposes. This determination was primarily based on the Legacy Gelesis’ stockholders comprising a relative majority of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7voting power of the ~~Investment Company Act, as determined~~combined company, the Legacy Gelesis’ operations prior to the acquisition comprising the only ongoing operations of Gelesis Holdings, the majority of Gelesis Holdings’ board of directors appointment by Legacy Gelesis, and Legacy Gelesis’ senior management comprising the ~~Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution~~entirety of the ~~funds in~~senior management of Gelesis Holdings. Accordingly, for accounting purposes, the ~~Trust Account, as described below.~~

~~Table~~consolidated financial statements of ~~Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~The Company’s management has broad discretion with respect to the specific application~~Gelesis Holdings will represent a continuation of the ~~net proceeds~~consolidated financial statements of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company’s initial Business Combination must beLegacy Gelesis with 1 or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (excluding taxes payable on interest income earned from the Trust Account and the deferred underwriting commissions) at the time of the agreement to enter into the initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

The Company will provide its holders of the outstanding Public Shares (the “public stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination ~~or (ii)~~being treated as the equivalent of Legacy Gelesis issuing stock for the net assets of CPSR, accompanied by ~~means~~a recapitalization. The net assets of ~~a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer~~CPSR will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to public stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 7). There will bestated at historical costs, with no ~~redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.~~

The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law or stock exchange requirements and the Company does not decide to hold a stockholder vote for businessgoodwill or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor has agreed to vote its Founder Shares (as defined in Note 6) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction.

Notwithstanding the above, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.

The Sponsor has agreed (i) to waive its redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination and (ii) not to propose an amendment to the Company’s Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their shares in conjunction with any such amendment.

~~Table of Contents~~intangible assets recorded.

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

Going Concern

The Company will have until July 7, 2022 to consummate a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ~~ten~~ business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay taxes (less up to $100,000 to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

The Sponsor has agreed to waive its right to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 7) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company’s auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

~~Risks and Uncertainties~~

Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of theseunaudited condensed consolidated financial ~~statements.~~statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might ~~result~~be necessary should the Company be unable to continue as a going concern.

The Company has a history of incurring substantial operating losses and has financed its operations primarily from the ~~outcome~~issuance of ~~this uncertainty.~~

~~Liquidity~~equity, promissory notes, government grants, supply and ~~Management’s Plan~~

~~As of September 30, 2021,~~distribution agreements and collaborations and licensing arrangements. The Company expects such operating losses and negative cash flows from operations will continue in 2022. Even with proceeds from the Business Combination, the Company ~~had $304,944~~expects its cash on hand as of the date of the condensed consolidated financial statements and collection of accounts and grants receivable will only be sufficient to meet the Company’s obligations into the first quarter of 2023,

and not at least twelve months beyond the date of issuance of the condensed consolidated financial statements. However, the extension of the Company's cash runway into the first quarter of 2023 is only achievable with the significant reduction of discretionary spending from prior levels, particularly with respect to the Company's discretionary sales and marketing activities and manufacturing and supply chain functions, and prior to considerations for any additional funding. These conditions raise substantial doubt about the Company’s ability to continue as a going concern and may adversely impact the sale of Plenity.

The Company will need to raise additional capital in future periods to fund its ~~operating bank accounts, $276,178,675 in securities held in~~operations. The Company will seek to raise necessary funds through a combination of equity issuances, debt financings, strategic collaborations and licensing arrangements, government grants, or other financing mechanisms. The Company’s ability to fund the ~~Trust Account to~~completion of its ongoing and planned clinical studies, as well as its regulatory and commercial efforts, may be ~~used for a Business Combination or to repurchase or redeem its common stock in connection therewith and working capital deficit of $2,265,312, which excludes $150,000 of franchise taxes payable.~~

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~On July 28, 2021, the Sponsor committed to provide~~substantially dependent upon whether the Company ~~an aggregate~~can obtain sufficient funding at acceptable terms. If adequate sources of $4,000,000 in loans for working capital purposes (see Note 6). These loans will be non-interest bearing, unsecured and will be repaid upon the consummation of a Business Combination. If the Company doesfunding are not ~~consummate a Business Combination, all amounts loaned~~available to the Company, ~~in connection with these loans will be forgiven except to the extent that~~ the Company ~~has funds available~~may be required to ~~it outside~~delay, reduce or eliminate research and development programs, reduce or eliminate commercialization efforts, and reduce its headcount. Additionally, the Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of ~~its Trust Account. As a result, management has determined that sufficient capital exists to sustain operations through the earlier~~failure of the ~~consummation of a Business Combination or July 7, 2022,~~full-scope product commercialization in targeted markets, clinical trials and preclinical studies, the ~~scheduled liquidation date~~impact of the ~~Company if a Business Combination is not completed.~~COVID-19 pandemic on the Company’s supply chain and results of operations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and development by competitors of technological innovations.

Summary of Significant Accounting Policies

Basis of Presentation

~~NOTE 2. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS~~

~~In connection with the preparation of the~~The Company’s condensed consolidated financial statements as of September 30, 2021, management identified errors made in its historical financial statements where, at the closing of the Company’s Initial Public Offering, the Company improperly valued its Class A common stock subject to possible redemption. The Company previously determined the Class A common stock subject to possible redemption to be equal to the redemption value, while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Management determined that the Public Shares underlying the Units issued during the Initial Public Offering can be redeemed or become redeemable subject to the occurrence of future events considered outside the Company’s control. Therefore, management concluded that temporary equity should include all shares of Class A common stock subject to possible redemption, resulting in the Class A common stock subject to possible redemption being equal to their redemption value. As a result, management has noted a classification error related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the Class A common stock subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and Class A common stock.

In connection with the change in presentation for the Class A common stock subject to possible redemption, the Company also restated its income (loss) per common share calculation to allocate net income (loss) evenly to Class A and Class B common stock. This presentation contemplates a Business Combination as the most likely outcome, in which case, both classes of common stock share pro rata in the income (loss) of the Company.

~~There has been no change in the Company’s total assets, liabilities or operating results.~~

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~The impact of the restatement on the Company’s condensed consolidated financial statements is reflected in the following table.~~

As Previously


Reported

Adjustment

As Restated
Balance Sheet as of July 7, 2020

Class A common stock subject to possible redemption

$
244,996,570

$
31,003,430

$
276,000,000
Class A common stock

$
310

$
(310)

$
—
Additional paid-in capital

$
5,671,903

$
(5,671,903)

$
—
Accumulated deficit

$
(672,901)

$
(25,331,217)

$
(26,004,118)
Total stockholders’ equity (deficit)

$
5,000,002

$
(31,003,430)

$
(26,003,428)
Number of shares subject to redemption

24,499,657

3,100,343

27,600,000

Balance Sheet as of September 30, 2020

Class A common stock subject to possible redemption

$
245,554,779

$
30,532,860

$
276,087,639
Class A common stock

$
305

$
(305)

$
—
Additional paid-in capital

$
5,113,699

$
(5,113,699)

$
—
Accumulated deficit

$
(114,691)

$
(25,418,856)

$
(25,533,547)
Total stockholders’ equity (deficit)

$
5,000,003

$
(30,532,860)

$
(25,532,857)
Number of shares subject to redemption

24,547,683

3,052,317

27,600,000

Balance Sheet as of December 31, 2020

Class A common stock subject to possible redemption

$
230,374,604

$
45,658,843

$
276,033,447
Class A common stock

$
457

$
(457)

$
—
Additional paid-in capital

$
20,293,722

$
(20,293,722)

$
—
Accumulated deficit

$
(15,294,860)

$
(25,364,664)

$
(40,659,524)
Total stockholders’ equity (deficit)

$
5,000,009

$
(45,658,843)

$
(40,658,834)
Number of shares subject to redemption

23,034,669

4,565,331

27,600,000

Balance Sheet as of March 31, 2021

Class A common stock subject to possible redemption

$
245,061,587

$
31,026,725

$
276,088,312
Class A common stock

$
311

$
(311)

$
—
Additional paid-in capital

$
5,606,885

$
(5,606,885)

$
—
Accumulated deficit

$
(607,876)

$
(25,419,529)

$
(26,027,405)
Total stockholders’ equity (deficit)

$
5,000,010

$
(31,026,725)

$
(26,026,715)
Number of shares subject to redemption

24,493,884

3,106,116

27,600,000

Balance Sheet as of June 30, 2021

Class A common stock subject to possible redemption

$
240,972,620

$
35,073,977

$
276,046,597
Class A common stock

$
352

$
(352)

$
—
Additional paid-in capital

$
9,695,811

$
(9,695,811)

$
—
Accumulated deficit

$
(4,696,850)

$
(25,377,814)

$
(30,074,664)
Total stockholders’ equity (deficit)

$
5,000,003

$
(35,073,977)

$
(30,073,974)
Number of shares subject to redemption

24,084,470

3,515,530

27,600,000

Statement of Operations for the Period from February 14, 2020 (Inception) Through September 30, 2020

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

24,499,657

(24,499,657)

—
Basic and diluted weighted average shares outstanding, Non-redeemable common stock

7,559,767

(7,559,767)

—
Basic and diluted net loss per share, Non-redeemable common stock

$
(0.02)

$
0.02

$
—
Weighted average shares outstanding of Class A common stock

—

10,761,468

10,761,468
Basic and diluted net loss per share, Class A common stock

$
—

$
(0.01)

$
(0.01)
Weighted average shares outstanding of Class B common stock

—

6,350,917

6,350,917
Basic and diluted net loss per share, Class B common stock

$
—

$
(0.01)

$
(0.01)

Statement of Operations for the Period from February 14, 2020 (Inception) Through December 31, 2020

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

24,524,620

(24,524,620)

—
Basic and diluted weighted average shares outstanding, Non-redeemable common stock

8,269,814

(8,269,814)

—
Basic and diluted net loss per share, Non-redeemable common stock

$
(1.85)

$
1.85

$
—
Weighted average shares outstanding of Class A common stock

—

15,758,710

15,758,710
Basic and diluted net loss per share, Class A common stock

$
—

$
(0.69)

$
—
Weighted average shares outstanding of Class B common stock

—

6,513,871

6,513,871
Basic and diluted net loss per share, Class B common stock

$
—

$
(0.69)

$
(0.69)

Statement of Operations for the Three Months Ended March 31, 2021

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

23,034,669

(23,034,669)

—
Basic and diluted weighted average shares outstanding, Non-redeemable common stock

11,465,331

(11,465,331)

—
Basic and diluted net income per share, Non-redeemable common stock

$
1.28

$
(1.28)

$
—
Weighted average shares outstanding of Class A common stock

—

27,600,000

27,600,000
Basic and diluted net income per share, Class A common stock

$
—

$
0.43

$
0.43
Weighted average shares outstanding of Class B common stock

—

6,900,000

6,900,000
Basic and diluted net income per share, Class B common stock

$
—

$
0.43

$
0.43

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

As Previously


Reported

Adjustment

As Restated
Statement of Operations for the Three Months Ended June 30, 2021

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

24,493,884

(24,493,884)

—
Basic and diluted weighted average shares outstanding, Non-redeemable common stock

10,006,116

(10,006,116)

—
Basic and diluted net loss per share, Non-redeemable common stock

$
(0.41)

$
0.41

$
—
Weighted average shares outstanding of Class A common stock

—

27,600,000

27,600,000
Basic and diluted net loss per share, Class A common stock

$
—

$
—

$
—
Weighted average shares outstanding of Class B common stock

—

6,900,000

6,900,000
Basic and diluted net loss per share, Class B common stock

$
—

$
(0.59)

$
(0.59)

Statement of Operations for the Six Months Ended June 30, 2021

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

23,768,307

(23,768,307)

—
Basic and diluted weighted average shares outstanding, Non-redeemable common stock

10,731,693

(10,731,693)

—
Basic and diluted net income per share, Non-redeemable common stock

$
0.99

$
(0.99)

$
—
Weighted average shares outstanding of Class A common stock

—

27,600,000

27,600,000
Basic and diluted net income per share, Class A common stock

$
—

$
0.31

$
0.31
Weighted average shares outstanding of Class B common stock

—

6,900,000

6,900,000
Basic and diluted net income per share, Class B common stock

$
—

$
0.31

$
0.31

Statement of Changes in Shareholders’ Equity (Deficit) for the Period from February 14, 2020 (Inception) Through September 30, 2020

Sale of 27,600,000 Units, net of underwriting discounts

$
249,366,073

$
(249,366,073)

$
—
Class A common stock subject to possible redemption

$
(245,554,775)

$
245,554,775

$
—
Accretion for Class A ordinary share subject to redemption amount

$
—

$
(26,721,566)

$
(26,721,566)
Total shareholders’ equity (deficit)

$
5,000,003

$
(30,532,860)

$
(25,532,857)

Statement of Changes in Shareholders’ Equity (Deficit) for the Period from February 14, 2020 (Inception) Through December 31, 2020

Sale of 27,600,000 Units, net of underwriting discounts

$
249,366,073

$
(249,366,073)

$
—
Class A common stock subject to possible redemption

$
(230,374,604)

$
230,374,604

$
—
Accretion for Class A ordinary share subject to redemption amount

$
—

$
(26,721,566)

$
(26,721,566)
Total shareholders’ equity (deficit)

$
5,000,009

$
(45,658,843)

$
(40,658,834)

Statement of Changes in Shareholders’ Equity (Deficit) for the Three Months Ended March 31, 2021

Class A common stock subject to possible redemption

$
(14,686,983)

$
14,686,983

$
—
Accretion for Class A ordinary share subject to redemption amount

$
—

$
(54,865)

$
(54,865)
Total shareholders’ equity (deficit)

$
5,000,010

$
(31,026,725)

$
(26,026,715)

Statement of Changes in Shareholders’ Equity (Deficit) for the Three Months Ended June 30, 2021

Class A common stock subject to possible redemption

$
(4,088,967)

$
4,088,967

$
—
Accretion for Class A ordinary share subject to redemption amount

$
—

$
41,715

$
41,715
Total shareholders’ equity (deficit)

$
5,000,003

$
(35,073,977)

$
(30,073,974)

Statement of Cash Flows for the Period of February 14, 2020 through September 30, 2020 (unaudited)






Initial classification of Class A common stock subject to possible redemption

$
244,996,570

$
31,003,430

$
276,000,000
Change in value of Class A common stock subject to possible redemption

$
558,209

$
(470,570)

$
87,639

Statement of Cash Flows for the Period of February 14, 2020 through December 31, 2020 (unaudited)

Initial classification of Class A common stock subject to possible redemption

$
244,996,570

$
31,003,430

$
276,000,000
Change in value of Class A common stock subject to possible redemption

$
(14,621,966)

$
14,655,413

$
33,447

Statement of Cash Flows for the Three Months Ended March 31, 2021

Change in value of Class A common stock subject to possible redemption

$
14,686,983

$
(14,598,671)

$
88,312

Statement of Cash Flows for the Six Months Ended June 30, 2021

Change in value of Class A common stock subject to possible redemption

$
10,598,016

$
(10,551,419)

$
46,597

~~NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES~~

~~Basis of Presentation~~

~~The accompanying unaudited condensed consolidated financial statements have been~~are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) ~~for interim financial information and~~. Any reference in ~~accordance with the instructions~~these notes to Form 10-Q and Article 8 of Regulation S-X promulgated under the Securities Act. Certain information or footnote disclosures normally included in condensed consolidated financial statements prepared in accordance with GAAP have been condensed

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~or omitted, pursuant~~applicable guidance is meant to refer to the ~~rules~~authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and ~~regulations of~~Accounting Standards Updates (“ASUs”) issued by the ~~SEC for interim~~Financial Accounting Standards Board (“FASB”).

The Company consolidates those entities where it has a direct and indirect controlling financial ~~reporting. Accordingly, they do not include all the information and footnotes necessary for~~interest based on either a ~~complete presentation of financial position, results of operations,~~variable interest model or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

voting interest model. The ~~accompanying unaudited condensed consolidated financial statements should be read in conjunction with the~~ Company’s Annual Report on Form 10-K/A, as filed with the SEC on July 8, 2021. The interim results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the period ending December 31, 2021 or for any future periods.

~~Principles of Consolidation~~

~~The accompanying~~ condensed consolidated financial statements include the accounts of the Company, its two wholly-owned subsidiaries and ~~its wholly-owned subsidiary.~~a variable interest entity (“VIE”), Gelesis S.r.l., in which the Company has a controlling interest and is the primary beneficiary. The noncontrolling interest attributable to the Company’s VIE is presented as a separate component from stockholders’ equity (deficit) in the condensed consolidated balance sheets and as a noncontrolling interest in the condensed consolidated statements of noncontrolling interest, redeemable convertible preferred stock and stockholders’ equity. All ~~significant~~ intercompany balances and transactions have been eliminated in consolidation.

~~Emerging Growth Company~~

~~The Company~~ Under the variable interest model, a controlling financial interest is ~~an “emerging growth company,” as defined in Section 2(a)~~determined based on which entity, if any, has (i) the power to direct the activities of the ~~Securities Act,~~VIE that most significantly impacts the VIE’s economic performance and (ii) the obligations to absorb losses that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. The consolidation status of a VIE may change as ~~modified by the Jumpstart Our Business Startups Act~~a result of ~~2012 (the “JOBS Act”), and it may take advantage~~such reassessments. Changes in consolidation status are applied prospectively in accordance with U.S. GAAP.

Reclassification of ~~certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply~~Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the ~~independent registered public accounting firm attestation requirements~~current year presentation. These reclassifications had no effect on the reported results of Section 404 of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

~~Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new~~operations or ~~revised~~ financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s condensed consolidated financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.position.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires ~~the Company’s~~ management to make estimates and assumptions that affect the reported amounts of assets, ~~and~~ liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of ~~revenues~~income and expenses during the reporting ~~periods.~~period. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.

Subsequent Event(s)

~~Making estimates requires management to exercise significant judgment. It is at least reasonably possible~~The Company considers events or transactions that occur after the ~~estimate of the effect of a condition, situation or set of circumstances that existed at the~~balance sheet date ofbut before the condensed consolidated financial statements ~~which management considered in formulating its estimate, could change in~~are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The Company evaluated all events and transactions through the ~~near term due to one or more future confirming events. One of the more significant accounting estimates included in~~date these condensed consolidated financial statements were filed with the Securities and Exchange Commission (“SEC”) or were available to be issued.

Fair Value of Financial Instruments

The guidance in FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority

to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:

Level 1 – Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair

~~Table~~ value hierarchy is based on the lowest level of ~~Contents~~any input that is significant to the fair value measurement.

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2 or Level 2 to Level 3.

The Company’s earnout liability, private placement warrants, and call option liability are recorded at fair value on a recurring basis. The carrying amount of accounts receivable, grants receivable, accounts payable and accrued expenses are considered a reasonable estimate of their fair value, due to the short-term maturity of these instruments. The carrying amount of notes payable is also considered to be a reasonable estimate of the fair value based on the nature of the debt and that the debt bears interest at the prevailing market rate for instruments with similar characteristics. The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above.

Earnout Liability: In connection with the Business Combination, Legacy Gelesis equityholders received the right to receive additional common stock upon the achievement of certain earnout targets. As the earnout consideration contains a settlement provision that precludes it from being indexed to the Company’s stock, it is classified as a liability held at fair value in accordance ASC 815 and the instrument is adjusted to fair value at each reporting period. In determining the fair value of the ~~warrant liabilities. Such estimates may be subject to change as more current information becomes available~~earnout liability at inception and ~~accordingly,~~on a recurring basis, the ~~actual results could differ significantly from those estimates.~~

~~Cash and Cash Equivalents~~

~~The~~ Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did 0t have any cash equivalents as of September 30, 2021 and December 31, 2020.

~~Marketable Securities Held in Trust Account~~

~~At September 30, 2021 and December 31, 2020, substantially all~~utilizes the Monte Carlo simulation value model where the fair value of the ~~assets~~earnout is the present value of a distribution of potential outcomes on a daily basis over the term of the earnout period.

Private Placement Warrant Liability: The Private Placement Warrants are recognized as liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities held at fair value and adjusts the instruments to fair value at each reporting period. In determining the fair value of the Private Placement Warrant liability, the Company utilized a modified Monte Carlo simulation value model at inception and on a recurring basis.

One Srl Call Option: In connection with the October 2020 amended agreement with One Srl, the Company granted One a contingent call option to buy back the 10% ownership that the Company acquired in the ~~Trust Account were~~2019 One Amendment. The One Srl call option was recorded as a liability held ~~in U.S. Treasury Bills. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the condensed consolidated balance sheet~~ at fair value at the ~~end~~date of issuance and is remeasured at each subsequent reporting ~~period. Gains and losses resulting from the change~~date with changes in fair value ~~of investments held~~recorded in ~~Trust Account are included in interest earned on marketable securities held in Trust Account~~other income (expense) in the accompanying condensed consolidated statements of operations. ~~The estimated fair values of investments held in Trust Account are~~Fair value is determined using ~~available market information.~~a Black-Scholes option pricing model.

Revenue Recognition

~~Warrant Liabilities~~Product Revenue

The Company ~~accounts for~~commercializes Plenity in the ~~Public Warrants (as defined~~U.S. markets principally through synergistic partnerships with online pharmacies and telehealth providers, which in ~~Note 3)~~turn sell Plenity directly to patients based on prescriptions. Outside the U.S., the Company primarily seeks collaborations with strategic partners to market Plenity and ~~Private Placement Warrants (together with~~obtain necessary regulatory approvals as necessary.

Product revenue is recognized by the ~~Public Warrants,~~Company in an amount that reflects the ~~“Warrants”) in accordance with the guidance contained in ASC 815-40, under~~consideration which the ~~Warrants~~Company expects to receive in exchange for those goods or services when the customer obtains control of the product, which occurs at a point in time, when the product is received by the Company's customers.

Reserves for Variable Consideration

Revenues from product sales are recorded as product revenue at the net sales price (transaction price), which includes estimates of variable consideration that are reimbursable to customers for which reserves are established and which result from (a) shipping charges to end-users, (b) pharmacy dispensing and platform fees, (c) merchant and processing fees, (d) promotional discounts offered by the Company to end-users, and (e) reserves for expected product quality returns. These reserves for contractual adjustments are

based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than the customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract(s). The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from the Company's estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. The Company has no plan to seek government or commercial payor reimbursements in the US or the overseas markets. Therefore, reserves for variable consideration do not ~~meet the criteria~~contain any components related to government and payor rebates or chargebacks.

Product Returns

The Company generally does not accept customer returns, except for ~~equity treatment and must be recorded as liabilities. Accordingly, the~~product quality related cases. The Company ~~classifies the Warrants as liabilities at their fair value~~evaluates quality related returns and adjusts the ~~Warrants to fair value in respect of each reporting period. This liability is subject to re-measurement~~corresponding product warranty reserves and liabilities at ~~each balance sheet date until the Warrants are exercised,~~least quarterly and any change in fair value is recognized in the statements of operations. The Private Placement Warrants and the Public Warrants for periods where no observable traded price was available are valued using a Monte Carlo simulation. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date.

~~Class A Common Stock Subject to Possible Redemption~~

The Company accounts for its shares of Class A common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s Class A common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s condensed consolidated balance sheets.

~~The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value~~ at the end of each reporting period. ~~Increases or decreases~~

Stock-Based Compensation

Effective January 1, 2020, the Company accounts for all stock-based compensation awards granted to employees and non-employees in accordance with ASC 718, Compensation – Stock Compensation. The Company’s stock-based compensation consist primarily of stock options. The measurement date for share-based awards is the date of grant, and stock-based compensation costs are recognized as expense over the respective requisite service periods, which are typically the vesting period. The fair value of each stock option grant is estimated as of the date of grant using the Black-Scholes option-pricing model that requires management to apply judgment and make estimates, including:

•

exercise price: The exercise price is the fair market value on grant date, which shall mean the closing sale price of common stock, as reported on such market on that date (or if there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations);

•

expected volatility: As the Company was previously a privately-owned company, there is not sufficient historical volatility for the expected term of the options. Therefore, the Company used an average historical share price volatility based on an analysis of reported data for a peer group of comparable companies for which historical information is available. For these analyses, the Company selects companies with comparable characteristics to itself including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The Company intends to consistently apply this process using representative companies until a sufficient amount of historical information regarding the volatility of its own share price becomes available;

•

risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption;

•

expected term, which is calculated using the simplified method, as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No. 107, Share-Based Payment, as the Company has insufficient historical information regarding its stock options to provide a basis for an estimate. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the stock options, taking into consideration multiple vesting tranches;

•

dividend yield, which is zero based on the fact that the Company never paid cash dividends and does not expect to pay any cash dividends in the ~~carrying amount~~foreseeable future.

Since the adoption of ~~redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit.~~

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~At September 30, 2021 and December 31,~~ASU 2018-07 on January 1, 2020, the ~~ordinary shares reflected~~measurement date for non-employee awards is the date of grant without changes in the fair value of the award. Stock-based compensation costs for non-employees are recognized as expense over the vesting period. Stock-based compensation expense is classified in the condensed consolidated ~~balance sheets~~statements of operations based on the function to which the related services are ~~reconciled~~provided. Forfeitures are recorded as they occur.

Business Combination and Reverse Recapitalization

As discussed in Note 1, on January 13, 2022, the ~~following table:~~

Gross proceeds

$
276,000,000
Less:


Proceeds allocated to Public Warrants

(11,454,000)
Ordinary shares issuance costs

(15,179,714)
Plus:


Accretion of carrying value to redemption value

26,667,374

Ordinary shares subject to possible redemption, 12/31/20

276,033,447
Accretion of carrying value to redemption value

(4,772)
Ordinary shares subject to possible redemption, 9/30/21

$
276,028,675

~~Income Taxes~~

~~The~~ Company ~~follows~~consummated the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the condensed consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assetsBusiness Combination pursuant to the ~~amount expected to be realized. The effective tax rates differ from~~Business Combination Agreement with CPSR dated July 19, 2021, as amended on November 8, 2021 and December 30, 2021. Concurrently

with the ~~statutory tax rate for~~execution of the ~~periods presented primarily due~~Business Combination Agreement, CPSR entered into subscription agreements with certain investors (the “PIPE Investors”). Pursuant to the ~~change in warrant valuation and~~subscription agreements, the ~~valuation allowance recorded on the Company’s net operating losses.~~

~~ASC 740 prescribes a recognition threshold and a measurement attribute for the condensed consolidated financial statement recognition and measurement~~PIPE Investors purchased an aggregate of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were 0 unrecognized tax benefits and 0 amounts accrued for interest and penalties as9,000,000 shares of September 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

~~Net Income (Loss) per Common Share~~

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company applies the two-class method in calculating income (loss) per common share. Accretion associated with the redeemable shares ofCPSR’s Class A common stock ~~is excluded from income (loss) per common share as the redemption value approximates fair value.~~

The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 21,320,000 shares in the calculation of diluted income (loss) per share, since the exercise of the warrants is contingent upon the occurrence of future events. As of September 30, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts):~~

For the Period from

Three Months Ended

Nine Months Ended

Three Months Ended

February 14,

September 30,

September 30,

September 30,

2020 (Inception) Through


2021

2021

2020

September 30, 2020


Class A

Class B

Class A

Class B

Class A

Class B

Class A

Class B
Basic and diluted net income (loss) per common share

Numerator:

Allocation of net income (loss), as adjusted

$
(11,404,326)

$
(2,851,082)

$
(89,850)

$
(23,841)

$
(2,925,918)

$
(731,480)

$
(72,126)

$
(42,565)
Denominator:









Basic and diluted weighted average stock outstanding

27,600,000

6,900,000

25,780,220

6,840,659

27,600,000

6,900,000

10,761,468

6,350,917
Basic and diluted net income (loss) per common share

$
(0.41)

$
(0.41)

$
(0.00)

$
(0.00)

$
(0.11)

$
(0.11)

$
(0.01)

$
(0.01)

~~Concentration of Credit Risk~~

~~Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account~~(the “PIPE Investment”) in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

~~Fair value of Financial Instruments~~

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature.

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:~~

~~Level 1:~~

Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

~~Level 2:~~

Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

~~Level 3:~~

~~Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.~~

~~Recent Accounting Standards~~

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 on January 1,2021. The adoption of ASU 2020-06 did not have an impact on the Company’s condensed consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.

~~NOTE 4. PUBLIC OFFERING~~

Pursuant to the Initial Public Offering, the Company sold 27,600,000 Units, which includes the full exercise by the underwriters of their option to purchase an additional 3,600,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of 1 share of Class A common stock and ~~one-half of one redeemable warrant (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase 1 share of Class A common stock~~private placement at a price of ~~$11.50~~$10.00 per share ~~subject to adjustment (see Note 9).~~

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~NOTE 5. PRIVATE PLACEMENT~~

Simultaneously with the closing of the Initial Public Offering, on July 7, 2020, the Sponsor purchased an aggregate of 7,520,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of ~~$7,520,000. Each Private Placement Warrant is exercisable~~$90.0 million. The PIPE Investment was consummated in connection with the closing. On December 30, 2021, CPSR entered into a backstop agreement (the “Backstop Agreement”) with certain investors (the “Backstop Investors”). Pursuant to ~~purchase 1 share~~the Backstop Agreement, the Backstop Investors purchased an aggregate of744,217 shares of CPSR’s Class A common stock in a private placement at a price of ~~$11.50~~$10.00 per ~~share.~~share for an aggregate purchase price of $7.4 million. Additionally, CPSR issued the Backstop Investors 1,983,750 shares of CPSR Class A common stock as additional consideration. The Backstop Agreement was consummated in connection with the closing.

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, CPSR, who was the legal acquirer, was treated as the acquired company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Gelesis issuing stock for the net assets of CPSR, accompanied by a recapitalization.

In connection with the Business Combination, the Company incurred approximately $37.2 million of costs, consisting of underwriting, legal, and other professional fees, $34.5 million of which were direct transaction costs and recorded to additional paid-in capital as a reduction of proceeds and $2.7 million of which were not directly attributable to the Business Combination and recorded as an expense in selling, general and administrative expense on the accompanying condensed consolidated statements of operations.

The following table summarizes the net proceeds from the ~~Private Placement Warrants were added~~Business Combination, as reconciled to the ~~proceeds from~~accompanying condensed consolidated statements of noncontrolling interest, redeemable convertible preferred stock and stockholder’s equity (deficit) and the ~~Initial Public Offering held~~condensed consolidated statements of cash flows:


	Amount
Cash - CPSR trust and cash (net of redemptions)	$	7,558
Cash - PIPE Investment		90,000
Cash - Backstop Agreement		7,442
Gross proceeds	$	105,000
Less: transaction costs, advisory fees and liabilities paid		(34,522	)
Net proceeds from the Business Combination	$	70,478

Immediately prior to closing of the Business Combination, Legacy Gelesis common stock was split according to the exchange ratio of 2.59, which was determined pursuant to the Business Combination Agreement and based on Legacy Gelesis’ implied price per share prior to the Business Combination. Upon closing of the Business Combination, holders received shares of common stock of the Company on a one-to-one basis. For periods prior to the Business Combination, in the ~~Trust Account. If~~accompanying condensed consolidated financial statements, the Company does not complete a Business Combination within the Combination Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.

~~NOTE 6. RELATED PARTY TRANSACTIONS~~

~~Founder Shares~~

On February 26, 2020, the Sponsor purchased 5,750,000 shares of the Company’s Class B common stock (the “Founder Shares”) for an aggregate price of $25,000. On July 1, 2020, the Company effected a stock dividend of 1,150,000 shares, resulting in the Company’s initial stockholders holding an aggregate of 6,900,000 Founder Shares. The Founder Shares included an aggregate of up to 900,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the Sponsor would own, on an as-converted basis, 20% of the Company’s issued and outstanding shares after the Initial Public Offering. Allreported share and ~~per-share~~per share amounts have been retroactively ~~restated~~converted (“Retroactive Application of Recapitalization”) by applying the exchange ratio. The consolidated assets, liabilities and results of operations prior to ~~reflect~~ the ~~stock dividend. As a result~~Business Combination are those of Legacy Gelesis

Immediately prior to the closing of the ~~underwriters’ election to fully exercise their over-allotment option, no Founder Shares are currently subject to forfeiture.~~

~~The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A) one year after the completion of a~~ Business Combination, ~~or (B) subsequent~~Legacy Gelesis redeemable convertible preferred stock converted into Legacy Gelesis common stock and was subsequently split according to athe exchange ratio of 2.59. Upon closing of the Business Combination, (x) if the last sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company’s stockholders having the right to exchange theirholders received shares of common stock ~~for cash, securities or other property.~~

~~Administrative Support Agreement~~

~~The Company entered into an agreement, commencing on July 1, 2020 through the earlier~~ of the ~~Company’s consummation of~~Company on a ~~Business Combination and its liquidation,~~one-to-one basis.

Immediately prior to pay an affiliate of the Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. For the three and nine months ended September 30, 2021, the Company incurred $30,000 and $90,000 in fees for these services, respectively. At September 30, 2021, $10,000 of such fees was included in account payable and accrued expense in the condensed consolidated balance sheet.

~~Promissory Note — Related Party~~

On February 14, 2020, the Sponsor agreed to loan the Company an aggregate of up to $250,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the earlier of July 31, 2020 or the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $140,000 was repaid at the closing of the ~~Initial Public Offering on July 7, 2020. Borrowings under the Promissory Note are no longer available.~~

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~Related Party Loans~~

~~In order to finance transaction costs in connection with a~~ Business Combination, ~~the Sponsor, an affiliate of the Sponsor, or the Company’s officers~~Legacy Gelesis stock options and ~~directors may, but are not obligated to, loan the Company funds as may be required~~restricted stock units (“~~Working Capital Loans”~~RSU”)~~. If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released~~ were split according to the ~~Company. In the event that a Business Combination does not close, the Company may use a portion~~exchange ratio of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. On March 3, 2021, the Sponsor committed to provide the Company an aggregate of $1,500,000 in loans for working capital purposes on an as needed basis. Such loans will be evidenced by a promissory note when issued. As of September 30, 2021 and December 31, 2020, there were no amounts outstanding under the Working Capital Loans.

~~Sponsor Loan~~

On July 28, 2021, the Sponsor committed to provide the Company an aggregate of $4,000,000 in loans for working capital purposes. These loans will be non-interest bearing, unsecured and will be repaid upon the consummation of a Business Combination. If the Company does not consummate a Business Combination, all amounts loaned to the Company in connection with these loans will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. As of September 30, 2021, there were 0 amounts outstanding under these loans.

~~NOTE 7. COMMITMENTS~~

~~Registration Rights~~

Pursuant to a registration rights agreement entered into on July 1, 2020, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any shares of Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) are entitled to registration rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to Class A common stock)2.59. The holders of the majority of these securities will be entitled to make up to 3 demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

~~Underwriting Agreement~~

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $9,660,000 in the aggregate. The deferred fee will be waived by the underwriters in the event that the Company does not complete a Business Combination, subject to the terms of the underwriting agreement.

~~Business Combination Agreement~~

~~On July 19, 2021, the Company entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “~~~~Business Combination Agreement~~~~”), by and among the Company, Merger Sub and Gelesis.~~

~~The Business Combination Agreement and the transactions contemplated thereby were approved by the board of directors of each of the Company and Gelesis.~~

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

The Business Combination Agreement provides for, among other things, that Merger Sub will merge with and into Gelesis, with Gelesis as the surviving company in the merger and, after giving effect to such merger, Gelesis shall be a wholly-owned subsidiary of the Company (the “Merger”). In addition, the Company will be renamed Gelesis Holdings, Inc. The Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the “Business Combination”.

~~In accordance with the terms and subject to the conditions~~Upon closing of the Business Combination, ~~Agreement, at the Effective Time, (i) each share~~holders of Legacy Gelesis ~~outstanding as of immediately prior~~stock options

received a stock option to ~~the Effective Time will be exchanged for~~purchase shares of the Company’s common stock ~~par value $0.0001 per share (“CPSR Shares”) based~~ on ~~an implied~~a one-to-one basis and holder of Legacy Gelesis equity value of $900,000,000; (ii) all vested and unvested stock options of Gelesis will be assumed by the Company and thereafter be settled or exercisable for CPSR Shares, as applicable, determined based on the same implied Gelesis equity value described in clause (i); (iii) each warrant of Gelesis will be canceled in exchange for a warrant to purchase sharesRSUs received RSUs of the Company ~~determined based~~ on a one-to-one basis.

Immediately prior to the ~~same implied Gelesis equity value described in clause (i); and (iv) each share~~closing of the ~~Company’s Class A~~Business Combination, Legacy Gelesis redeemable preferred stock warrants were converted into Legacy Gelesis common warrants and were subsequently split according to the exchange ratio of 2.59. Upon closing of the Business Combination, holders received shares of common stock ~~par value $0.0001 per share (the “~~~~CPSR Class A~~~~Common Stock~~~~”) and each share~~ of the ~~Company’s Class B~~Company on a one-to-one basis.

Immediately prior to the closing of the Business Combination, Legacy Gelesis common warrants were split according to the exchange ratio of 2.59. Upon closing of the Business Combination, holders received shares of common stock ~~par value $0.0001 per share (the “~~~~CPSR Class B Common~~~~Stock~~~~”) that is~~of the Company on a one-to-one basis.

The number of shares of common stock issued and outstanding immediately ~~prior to the Effective Time shall become 1 CPSR Share~~ following the consummation of the Business ~~Combination.~~ Combination was as follows:


	Common Stock
CPSR Public Stockholders		755,223
CPSR Sponsor Stockholders		4,916,250
Total CPSR Stockholders		5,671,473
Common stock issued to Gelesis Legacy Equityholders		54,814,847
Common stock issued to PIPE Investors and Backstop Agreement		11,727,967
Total common stock immediately after Closing		72,214,287

Earnout Shares

In addition, each holder of ~~shares of~~Legacy Gelesis common stock, Legacy Gelesis options and Legacy Gelesis warrants will receive ~~its~~a pro rata portion of ~~15,000,000~~up to 23,482,845 restricted ~~earn out CPSR Shares,~~earnout shares of Gelesis Holding’s common stock, which will be issued and vest ~~(in part)~~ in equal thirds if the trading price of ~~CPSR Shares~~the Company’s common stock is greater than or equal to ~~$12.50, $15.00~~$12.50, $15.00 and ~~$17.50,~~$17.50, respectively, for any twenty (20) trading days within any thirty (30)-trading day period on or prior to the date that is five years following the ~~Effective Time (the “Earn Out Period”)~~close of the Business Combination and will also vest in connection with any ~~Change~~change of ~~Control Transaction~~control transaction with respect to the Company if the applicable thresholds are met in such ~~Change~~change of ~~Control Transaction~~control transaction during the ~~Earn Out Period.~~earnout period (each a “Triggering Event”).

On November 8, 2021, CPSR, Merger Sub and Gelesis entered into an Amendment to the Original Business Combination Agreement (the “Business Combination Agreement Amendment,” and together with the Original Business Combination Agreement, the “Business Combination Agreement”), which, among other things (i) adjusts the equity valuation of Gelesis from $900,000,000 to $675,000,000, (ii) increases the number of Earn Out Shares (as defined in the Business Combination Agreement) available to be issued toThe Company Stockholders (as defined in the Business Combination Agreement) from 15,000,000 to 23,483,250, (iii) provides for the issuance of 1,983,750 additional Capstar Class A Shares to Company Stockholders, equal to the number of Capstar Class B Shares forfeited by the Sponsor and certain affiliates of the Sponsordetermined 18,758,241 earnout shares are considered a contingent consideration arrangement in accordance with ASC 815, and recorded a liability upon the Sponsor Letter Agreement Amendment (as defined and described in further detail below), and (iv) extends the Termination Date (as defined in the Business Combination Agreement) from January 18, 2022 to January 31, 2022.

~~In connection, and concurrently, with the execution~~closing of the Business Combination ~~Agreement Amendment, Capstar, Capstar Sponsor Group LLC, a Delaware limited liability company (the “Sponsor”), certain affiliates~~of $58.9 million (see Note 14). The Company determined the remaining 4,724,604 earnout shares, which pertain to Legacy Gelesis equity awards, are incremental compensation in accordance with ASC 718 and equity classified. The total fair value of incremental compensation cost at the close of Business Combination was $14.8 million which will be expensed according to the vesting terms of the ~~Sponsor~~original underlying equity awards. The total incremental compensation cost, pertaining to Legacy Gelesis equity awards which had previously vested, was $11.4 million, of which $7.0 million and $4.4 million was recognized immediately following the close of the Business Combination as expense in selling, general and administrative expense and research and development expense, respectively, in the accompanying condensed consolidated statements of operations.

Public Warrants and Private Placement Warrants

Upon the closing of the Business Combination, the Company assumed 13,800,000 Public Warrants and 7,520,000 Private Placement Warrants. The Company determined the Public Warrants qualified as equity instruments in accordance with ASC 815 and reclassified the Public Warrants from liability to equity classification and the carrying value of $7.1 million was transferred to APIC on the accompanying condensed consolidated balance sheets. The Company determined the Private Placement Warrants met the definition of

a liability under ASC 815 and recorded a liability reflecting the fair value of the Private Placement Warrants of $8.1 million. See Note 13 and Note 15 for further information on the Private Placement and Public Warrants, respectively.

Fair Value Measurements

Liabilities that are measured at fair value on a recurring basis, and the level of the fair value hierarchy utilized to determine such fair values, consisted of the following at March 31, 2022 (in thousands):


			Fair Value Measurements
	Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Earnout liability (See Note 14)	$	25,002	$	—	$	—	$	25,002
Private placement warrant liability (see Note 13)		3,730		—		—		3,730
One Srl call option (see Note 11)		2,623		—		—		2,623
Total liabilities measured at fair value	$	31,355	$	—	$	—	$	31,355

Liabilities that are measured at fair value on a recurring basis, and the level of the fair value hierarchy utilized to determine such fair values, consisted of the following at December 31, 2021 (in thousands):


			Fair Value Measurements
	Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Convertible promissory notes (see Note 12)	$	27,128	$	—	$	—	$	27,128
Legacy Gelesis preferred stock warrants (See Note 13)		15,821		—		—		15,821
One Srl call option (see Note 11)		2,416		—		—		2,416
Total liabilities measured at fair value	$	45,365	$	—	$	—	$	45,365

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments during the three months ended March 31, 2022:


	Convertible Promissory Notes			Legacy Gelesis Redeemable Preferred Stock Warrants Liabilities			One Srl Call Option			Earnout Liability			Private Placement Warrant Liability
Balance at December 31, 2021	$	27,128		$	15,821		$	2,416		$	—		$	—
Assumed upon Business Combination		—			—			—			—			8,140
Recognized upon Business Combination		—			—			—			58,871			—
Changes in fair value		156			926			258			(33,869	)		(4,410	)
Foreign currency translation (gain)/loss		—			—			(51	)		—			—
Conversion and exchange upon Business Combination		—			(16,747	)		—			—			—
Settlement		(27,284	)
Balance at March 31, 2022	$	—		$	—		$	2,623		$	25,002		$	3,730

There were 0 transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three months ended March 31, 2022. The fair value measurement of the convertible promissory notes, Legacy Gelesis ~~entered into~~preferred stock warrant liability, One Srl call option liability, earnout liability and private placement warrant liability utilized inputs not observable in the market and thus represents a Level 3 measurement.

Product Revenue Reserve and Allowance

The Company sells the Product principally to a limited number of customers consisting of telemedicine and online pharmacies, that in turn resell the Product to end-user patients and healthcare providers. Patients are required to have a prescription in order to purchase the Product in the United States.

Roman Health Pharmacy LLC

During the three months ended March 31, 2022 and 2021, the Company recognized $6.7 million and $2.9 million, respectively, of product revenue, net, in the accompanying condensed consolidated statements of operations with respect to Roman Health Pharmacy LLC, or Ro. At March 31, 2022 and December 31, 2021, the Company recorded a deferred income balance of $24.2 million and $31.0 million, respectively, in the accompanying condensed consolidated balance sheets with respect to Ro.

GoGoMeds

During three months ended March 31, 2022 and 2021, the Company recognized $1.1 million and $0.1 million, respectively, of product revenue, net, in the accompanying condensed consolidated statements of operations with respect to Specialty Medical Drugstore, LLC, d/b/a/ GoGoMeds, or GGM. At March 31, 2022 and December 31, 2021, the Company recorded an ~~amendment (the “Sponsor Letter Agreement Amendment”)~~accounts receivable balance of $0.8 million and $0.8 million, respectively, prior to ~~that certain Sponsor Letter Agreement, dated July 19, 2021. Pursuant~~reserves and allowances, in the accompanying condensed consolidated balance sheets with respect to GGM.

CMS Bridging DMCC

At March 31, 2022 and December 31, 2021, the discounted time-based milestone had a balance of $4.1 million and $4.1 million, respectively, included in other assets in the accompanying condensed consolidated balance sheets. The royalties and other commercial milestones will only be recognized in the periods in which the applicable subsequent sales occur.

Total Product Revenue, net and Reserves

During the three months ended March 31, 2022 and 2021, the Company recognized $7.5 million and $3.1 million, respectively, of product revenue, net in the accompanying condensed consolidated statements of operations. At March 31, 2022 and December 31, 2021, the Company had accounts receivable of $0.8 million and $0.7 million, respectively, prior to reserves and allowances. The following table summarizes the activity in the product revenue reserve and allowance during the three months ended March 31, 2022 and 2021 (in thousands):


	At March 31,
	2022			2021
Balance at December 31,	$	82		$	14
Provision related to product sales		574			295
Credits and payments made		(418	)		(297	)
Balance at March 31,	$	238		$	12

At March 31, 2022 and 2021, product related reserve and allowances comprised solely contractual adjustments owed to the ~~Sponsor Letter~~Company’s telehealth and online pharmacy partners, which were netted to accounts receivable in the Company’s condensed consolidated balance sheets for the year. Through March 31, 2022, there had been no product related reserves or allowances owed to other parties, including the federal and state governments or their agencies.

Inventories

Inventories consisted of the following (in thousands):


	March 31,		December 31,
	2022		2021
Raw materials	$	9,031	$	8,074
Work in process		2,962		2,643
Finished goods		4,283		2,786
Total inventories	$	16,276	$	13,503

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	March 31,		December 31,
	2022		2021
Prepaid expenses	$	1,892	$	982
Prepaid insurance		1,279		55
Prepaid manufacturing expenses		1,530		2,624
Prepaid contract research costs		201		262
Research and development tax credit		248		579
Value added tax receivable		6,145		5,633
Deferred financing costs		222		3,855
Income tax receivable		210		213
Investment tax credit		1,316		0
Prepaid expenses and other current assets	$	13,043	$	14,203

Property and Equipment, Net

Property and equipment, net, consists of the following (in thousands):


	March 31,			December 31,
	2022			2021
Laboratory and manufacturing equipment	$	28,269		$	28,101
Land and buildings		10,783			10,404
Leasehold improvements		1,582			1,614
Computer equipment and software		476			463
Capitalized software		232			228
Construction in process		22,295			22,097
Property and equipment – at cost		63,637			62,907
Less accumulated depreciation		(5,316	)		(4,392	)
Property and equipment – net	$	58,321		$	58,515

The Company owns and operates commercial manufacturing and research and development facilities in Italy, including a 51,000 square foot facility, which the Company expects to further expand to a 88,600 square foot facility, as well as approximately 12 acres of land, where the Company initiated construction of an additional 207,000 square foot facility. Both facilities are near the Town of Lecce in the Puglia region of Italy. Property and equipment classified as construction in process at March 31, 2022 and December 31, 2021 are related to the development of manufacturing lines that have not yet been placed into service at March 31, 2022 and December 31, 2021, respectively.

Depreciation expense was approximately $1.0 million and $0.2 million during the three months ended March 31, 2022 and 2021, respectively.

Accrued Expenses

Accrued expenses and other current liabilities consist of the following (in thousands):


	March 31,		December 31,
	2022		2021
Accrued payroll and related benefits	$	1,835	$	1,384
Accrued professional fees and outside contractors (including due to related party of $156 and $60, respectively)		2,494		4,359
Accrued property, plant and equipment additions		1,557		1,257
Accrued inventory and manufacturing expense		268		128
Unpaid portion of acquisition of intangible asset and investment in related party (see Note 11)		2,778		5,604
Income taxes payable		96		145
Deferred legal fees		738		738
Accrued interest		358		45
Total accrued expenses	$	10,124	$	13,660

10.

Other Long-Term Liabilities

Other long-term liabilities consist of the following (in thousands):


	March 31,		December 31,
	2022		2021
Long-term tax liabilities		90		182
Contingent loss for research and development tax credits		2,930		2,990
One Srl call option (see Note 11)		2,623		2,416
Total other long-term liabilities	$	5,643	$	5,588

11.

Significant Agreements

Puglia 1 Grant

In May 2020, the Company was awarded a grant by the Puglia region of Italy as an incentive to manufacture and carry out research and development activities in Italy (“PIA 1 Grant”), The Company recognized grant income of $0.2 million and $0.1 million in other income, net, on the accompanying condensed consolidated statements of operations during the three months ended March 31, 2022 and 2021, respectively, related to the PIA 1 Grant, of which less than $0.1 million and $0.2 million was attributable to research and development expenses and investments in facilities and equipment, respectively, during the three months ended March 31, 2022 and less than $0.1 million was attributable to both research and development expenses and investments in facilities and equipment, respectively, during the three months ended March 31, 2021. The Company recorded $6.1 million and $6.4 million of deferred income in the accompanying condensed consolidated balance sheets at March 31, 2022 and December 31, 2021, respectively, of which $0.8 million and $0.9 million was recorded as a current liability, respectively, as it is expected to be recognized within one year of the date of the accompanying condensed consolidated balance sheets. The Company collected 0 proceeds from the PIA 1 Grant during the three months ended March 31, 2022, and recorded a grant receivable of $5.3 million and $5.4 million in the accompanying condensed consolidated balance sheets at March 31, 2022 and December 31, 2021, respectively.

Puglia 2 Grant

In November 2020, the Company was awarded a second grant by the Puglia region of Italy as an incentive to manufacture and carry out research and development activities in Italy (“PIA 2 Grant”), The Company recognized grant income of $0.2 million and $0.5 million in other income, net, on the accompanying condensed consolidated statements of operations during the three months ended March 31, 2022, and 2021, respectively, related to the PIA 2 Grant, which was entirely attributable to research and development expenses. The Company has recorded $3.7 million and $3.7 million of deferred income in the accompanying condensed consolidated balance sheets at March 31, 2022 and December 31, 2021, respectively, of which $0.1 million and less than $0.1 million was recorded as a current liability, respectively, as it is expected to be recognized within one year of the date of the accompanying condensed consolidated balance sheets. The Company collected 0 proceeds from the PIA 2 Grant during the three months ended March 31, 2022, and has recorded a grant receivable of $3.8 million and $3.6 in the accompanying condensed consolidated balance sheets at March 31, 2022 and December 31, 2021, respectively.

One S.r.l. (“One”) Amended Patent License and Assignment Agreement

In June 2019, the Company amended and restated an existing master agreement with One (the “2019 One Amendment”), the original inventor of the Company’s core patents and a related party to the Company (see Notes 19 and 20). Under the amended and restated master agreement following this transaction, the Company eliminated certain future commercial milestone obligations and received a reduction in the percentage of royalties the Company was required to pay on future net sales. In return, One received additional consideration consisting of new future milestones upon the commercial success of new medical indications and a contingently issuable warrant for redeemable convertible preferred stock. Additionally, the Company acquired a 10% equity interest in One in exchange for cash consideration.

The Company accounted for the reduction in royalties the Company is required to pay on future net revenues that resulted from the 2019 One Amendment as an intangible asset under ASC 350, Intangibles – Goodwill and Other, which shall be amortized over its useful life, which was determined to be the ~~parties thereto~~earliest expiration of patents related to the underlying intellectual property in November 2028. The Company accounted for the acquisition of the 10% equity interest in One under ASC 323, Investments – Equity Method and Joint Ventures.

In connection with the acquisition of the 10% equity interest in One, the Company made a payment of $2.9 million to One shareholders during the three months ended March 31, 2022. The Company had remaining undiscounted payments of €2.5 million and

€5.0 million due to One at March 31, 2022 and December 31, 2021, respectively (approximately $2.8 million and $5.7 million due to One at March 31, 2022 and December 31, 2021, respectively). The remaining payments at March 31, 2022 were recorded in accrued expenses in the accompanying condensed consolidated balance sheets as it is expected to be settled within the next twelve months. None of the future milestones under the amended and restated master agreement, have been met, or are deemed to be probable of being met, at the transaction date or at March 31, 2022 and December 31, 2021, respectively.

A summary of the intangible asset activity that resulted from this transaction during the three months ended March 31, 2022 is as follows (in thousands):


	Intangible Assets
Intangible asset at relative fair value	$	15,564
Adjustment to record deferred tax liability		5,783
Carrying value of intangible asset at June 2019 acquisition date	$	21,347
Cumulative amortization expense		(5,667	)
Balance at December 31, 2021	$	15,680
Period amortization expense		(567	)
Balance at March 31, 2022	$	15,113

In October 2020, the Company further ~~agreed, among other things,~~amended the terms of the agreement with One to cancels its obligation to issue a warrant for redeemable convertible preferred stock in the 2019 One Amendment for additional commercial milestone consideration and a warrant to purchase common stock. Additionally, the Company granted One a contingent call option to buy back the 10% ownership that ~~(i)~~ the ~~vesting provisions relating to Capstar Class B Shares (as~~Company acquired in the 2019 One Amendment at an exercise price of €6.0 million (approximately $6.6 million at March 31, 2022). The call option is only exercisable upon (1) a change of control or a deemed liquidation event by the Company, as defined, in the ~~Sponsor Letter Agreement)~~Company’s Restated Certification of Incorporation (2) the date in which the Company’s current Chief Executive Officer is no longer affiliated with the Company in his capacity as either an executive officer or a member of the board of directors.

The One Srl call option was recorded as a liability held at fair value at the date of issuance and is remeasured at each subsequent reporting date with changes in fair value recorded in other income (expense) in the accompanying condensed consolidated statements of operations. Fair value is determined using a Black-Scholes option pricing model. The significant inputs used in estimating the fair value of call option liability include the estimated fair value of the underlying stock price, expected term, risk free interest rate, and expected volatility.

The following represents a summary of the changes to Company’s One Srl call option liability during the three months ended March 31, 2022 (in thousands):


Balance at December 31, 2021	$	2,416
Change in fair value		258
Foreign currency translation gain		(51	)
Balance at March 31, 2022	$	2,623

The following weighted average assumptions were used to determine the fair value of the One Srl call option liability at March 31, 2022 and December 31, 2021:


	March 31,			December 31,
	2022			2021
Expected term	4.0 years			2.0 years
Expected volatility		65.0	%		62.0	%
Expected dividend yield		0.0	%	0.0%
Risk free interest rate		2.5	%		0.70	%
Estimated fair value of ownership interest	$	5,623		$	6,922
Exercise price of call option	$	6,668		$	6,806

Research Innovation Fund (“RIF”) Financing

In August 2020, the Gelesis S.r.l. entered into a loan and equity agreement with RIF, an investment fund out of the EU, whereby Gelesis S.r.l. received €10.0 million (approximately $11.1 million at March 31, 2022) from RIF as an equity investment and €15.0 million (approximately $16.7 million at March 31, 2022) as a loan with a fixed interest rate of 6.35% per annum (see Note 12). The equity investment can be ~~deleted~~called by the Company, beginning in December 2023 and ~~(ii)~~ending in December 2026, by paying the investment plus 15% percent annual interest. If the Company does not exercise this call option, beginning in January 2027 and ending in December 2027, RIF may put the investment to the Company at a cost of the investment amount plus 3.175% percent annual interest. The loan has a termination date of December 31, 2030 and is repayable over 8 years starting 24 months subsequent to its

issuance. Any unpaid principal and interest must be repaid upon exercise of the call option by the Company, or subsequent exercise of a put option by RIF. At March 31, 2022, RIF holds approximately 20% of the equity of Gelesis S.r.l.

The Company recorded accretion of less than $0.1 million and foreign currency translation gain of $0.2 million to the noncontrolling interest during the three months ended March 31, 2022. The noncontrolling interest balance was $11.7 million and $11.9 million at March 31, 2022 and December 31, 2021, respectively, in the accompanying condensed consolidated balance sheets.

12.

Debt

The Company’s non-convertible debt outstanding at March 31, 2022 and December 31, 2021 is summarized as follows:


	March 31,			December 31,
	2022			2021
Italian Economic Development Agency Loan		344			525
Intesa Sanpaolo Loan 1		8,097			8,507
Intesa Sanpaolo Loan 2		5,557			5,672
Horizon 2020 Loan		477			486
RIF Shareholders Loan		16,672			17,015
UniCredit Loan		5,517			5,630
Total debt obligation	$	36,664		$	37,835
Unamortized loan discount and issuance costs		(705	)		(754	)
Total debt obligation carrying amount	$	35,959		$	37,081
Current portion	$	2,001		$	1,950
Long-term portion	$	33,958		$	35,131

2021 Bridge Financing

On December 13, 2021, the Company issued convertible promissory notes to related parties in the principal amount of $27.0 million (see Note 20). At December 31, 2021, the outstanding balance was $27.1 million, recorded at fair value in the accompanying condensed consolidated balance sheets. On January 19, 2022 the Company settled the convertible promissory notes in cash for principal plus accrued interest in the aggregate amount of $27.3 million. During the three months ended March 31, 2022, the Company recognized a loss of $0.2 million with respect to the change in fair value of the convertible promissory notes on the accompanying condensed consolidated statements of operations.

Future maturities with respect to debt outstanding at March 31, 2022 are as follows (in thousands):


	At March 31, 2022
Remaining 2022 obligation		1,729
2023		8,413
2024		5,655
2025		4,114
2026		4,136
More than 5 years		12,618
Unamortized loan discount and issuance costs		(705	)
Total debt obligation carrying amount	$	35,959
Current portion	$	2,001
Long-term portion	$	33,958

13.

Warrant Liabilities

The following represents a summary of the warrant liabilities activity during the three months ended March 31, 2022 :


	Series A-4 Warrants			Private Placement Warrants			Total
Balance at December 31, 2021	$	15,821		$	—		$	15,821
Assumed upon Business Combination		—			8,140			8,140
Changes in fair value		926			(4,410	)		(3,484	)
Conversion and exchange upon Business Combination		(16,747	)		—			(16,747	)
Balance at March 31, 2022	$	—		$	3,730		$	3,730

Private Placement Warrants

At March 31, 2022, there were 7,520,000 Private Placement Warrants outstanding exercisable at $11.50 per share for common stock at the same terms as the Public Warrants. However, the warrants will not be redeemable by the Company for cash so long as they are held by the initial stockholders or their permitted transferees. The initial purchasers of the Private Placement Warrants, or their permitted transferees, also have the option to exercise the Private Placement Warrants on a cashless basis. If Private Placement Warrants are held by holders other than the initial purchasers thereof or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants.

The warrants were initially recorded at fair value with subsequent changes in fair value being recorded in the accompanying condensed consolidated statements of operations. The warrants at issuance and at March 31, 2022, were valued utilizing a modified Monte Carlo Simulation value model and significant unobservable Level 3 inputs.

The following weighted-average assumptions were used to determine the fair value of the Private Placement Warrant liability at March 31, 2022:


	Private Placement Warrants
Expected term	4.8 years
Expected volatility		40.0	%
Expected dividend yield		0.0	%
Risk free interest rate		2.4	%
Price of Gelesis Common Stock	$	4.53
Exercise price of warrants	$	11.50

Legacy Gelesis Redeemable Preferred Stock Warrants

In connection with the Business Combination, Legacy Gelesis redeemable preferred stock warrants were reclassified from liability treatment to equity treatment pursuant to the terms of their exchange (see Note 15).

14.

Earnout Liability

The following represents a summary of the earnout liability activity during the three months ended March 31, 2022:


	Earnout Liability
Balance at December 31, 2021	$	—
Recognized upon Business Combination		58,871
Changes in fair value		(33,869	)
Balance at March 31, 2022	$	25,002

At Business Combination close and at March 31, 2022, there were 18,758,241 earnout shares unissued and unvested. At March 31, 2022, none of the triggering events had been met.

The earnout liability was initially recorded at fair value with subsequent changes in fair value being recorded in the accompanying condensed consolidated statements of operations. The earnout liability at issuance and at March 31, 2022, were valued utilizing a Monte Carlo Simulation and significant unobservable Level 3 inputs.

The following weighted-average assumptions were used to determine the fair value of the earnout liability at March 31, 2022:


	Earnout Liability
Expected term	4.8 years
Expected volatility		40.0	%
Expected dividend yield		0.0	%
Risk free interest rate		2.4	%
Price of Gelesis Common Stock	$	4.53

15.

Stockholder's Equity (Deficit)

Common Stock

The Company’s authorized capital stock consists of (a) 900,000,000 shares of common stock, par value $0.0001 per share; and (b) 250,000,000 shares of preferred stock, par value $0.0001 per share. At March 31, 2022, there were 72,390,413 shares of common stock issued and outstanding.

Legacy Redeemable Convertible Preferred Stock

At December 31, 2021 and immediately prior to the Effective Time (as defined in the Sponsor Letter Agreement), 1,983,750 Capstar Class B Shares held by the Sponsor and certain affiliates of the Sponsor be surrendered to Capstar for cancellation upon such surrender, without any consideration for such surrender.

~~The~~ Business Combination, ~~is expected to close in the fourth quarter of 2021, following the receipt of the required approval by the Company’s stockholders~~Legacy Gelesis had outstanding Series A-1, Series A-2, Series A-3, Series A-4, Series A-5, Series Growth, Series 2 Growth and ~~the fulfillment of other customary closing conditions.~~

~~NOTE 8. STOCKHOLDERS’ DEFICIT~~

~~Preferred Stock~~~~—The Company is authorized to issue 1,000,000 shares of~~Series 3 Growth redeemable convertible preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At September 30, 2021 and December 31, 2020, there were 0 shares of preferred stock issued or outstanding.

~~Class A Common Stock~~—On February 26, 2020, the Company amended its Certificate of Incorporation such that the Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~stock are entitled to 1 vote for each share. At September 30, 2021 and December 31, 2020, there were 27,600,000 shares of Class A common stock issued and outstanding,~~ which are ~~subject~~collectively referred to ~~possible redemption and classified~~ as ~~temporary equity.~~“redeemable convertible preferred stock.”

~~Class B Common Stock~~—On February 26, 2020, the Company amended its Certificate of Incorporation such that the Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to 1 vote for each share. At September 30, 2021 and December 31, 2020, there were 6,900,000 shares of Class B common stock issued and ~~outstanding~~.

~~Holders of Class B common stock will have the right to elect all of the Company’s directors~~Immediately prior to a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law.

The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of a Business Combination on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the Initial Public Offering and related to the closing of athe Business Combination, ~~the ratio at which shares of Class B~~Legacy Gelesis redeemable convertible preferred stock converted into Legacy Gelesis common stock ~~shall convert into shares~~and was subsequently split according to the exchange ratio of ~~Class A common stock will be adjusted (unless the holders of a majority~~2.59. Upon closing of the outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of allBusiness Combination, holders received shares of common stock ~~outstanding upon the completion~~ of the ~~Initial~~ Company on a one-to-one basis.

Public ~~Offering plus all shares of Class A~~Warrants

In connection with the Business Combination the Company assumed 13,800,000 Public Warrants, which entitle the holder to acquire common stock, and equity-linked securities issued or deemed issued in connection with a Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in a Business Combination, and any private placement-equivalent warrants issued to the Sponsor or its affiliates upon conversionwhich are exercisable at an exercise price of ~~loans made to the Company).~~

$11.50

~~NOTE 9. WARRANTS~~

As of September 30, 2021 and December 31, 2020, there were 13,800,000 Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. per share. The Public Warrants will expire at on the earlier to occur of five years after the completion of athe Business Combination or ~~earlier upon redemption or liquidation.~~

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and we will not be obligated to issue shares of Class A common stock upon exercise of a warrant unless Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.redemption.

~~The Company has agreed that as soon as practicable, but in no event later than~~ 15 business days after the closing of a Business Combination, the Company will use its best efforts to file with the SEC a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the 60_th business day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

Once the ~~warrants~~Public Warrants become exercisable, the Company may ~~redeem~~call the Public ~~Warrants:~~Warrants for redemption for cash:

●

~~in whole and not in part;~~

●

~~at a price of $0.01 per warrant;~~

●

~~upon not less than 30 days’ prior written notice of redemption to each warrant holder; and~~

●

if, and only if, the reported last sale price of the Company’s Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30

•

in whole and not in part;

•

at a price of $0.01 per warrant;

•

upon not less than thirty (30) days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and

•

if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any twenty(20) trading days within a thirty (30)-trading day period ending 3 (3) business days before ~~the Company sends the notice of redemption to the warrant holders.~~

~~If and when the warrants become redeemable by~~ the Company sends the ~~Company may not exercise its~~notice of redemption ~~right if~~to the issuance of shares of common stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or the Company is unable to effect such registration or qualification.

warrant holders.

If the Company calls the Public Warrants for redemption, ~~management~~the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a ~~“cashless~~cashless basis,” as described in the warrant agreement. The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of Class A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash ~~settle~~settle.

At March 31, 2022, there were 13,800,000 Public Warrants outstanding.

Rollover Warrants

Immediately prior to the ~~warrants. If~~closing of the ~~Company is unable to complete a~~ Business Combination, ~~within~~Legacy Gelesis redeemable preferred stock warrants were converted into Legacy Gelesis common warrants and were subsequently split according to the ~~Combination Period and the Company liquidates the funds held in the Trust Account, holders~~exchange ratio of ~~warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside~~2.59. Upon closing of the ~~Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.~~

~~In addition, if (x) the Company issues additional~~Business Combination, holders received shares of common stock ~~or equity-linked securities~~of the Company on a one-to-one basis. At close of Business Combination and March 31, 2022, there were 1,836,429 and 1,660,303 warrants outstanding, respectively, with an exercise price of $0.02. During the three months ended March 31, 2022, 176,126 rollover warrants were exercised for ~~capital raising purposes in connection with~~proceeds of less than $0.1 million.

Immediately prior to the closing of athe Business Combination, existing Legacy Gelesis common warrants were also split according to the exchange ratio of 2.59. Upon closing of the Business Combination, holders received shares of common stock of the Company on a

one-to-one basis. At close of Business Combination and at March 31, 2022, respectively, there were 1,353,062 of these warrants outstanding with an ~~issue price or effective issue~~exercise price of ~~less than $9.20 per share (with such~~$4.26.

At March 31, 2022 and December 31, 2021 common stock reserved for future issuances was as follows:


	March 31,		December 31,
	2022		2021
Common stock issued upon option exercise and RSUs vesting		20,417,412		13,486,708
Conversion of all classes of redeemable convertible preferred stock		—		48,566,655
Issuances upon exercise of warrants to purchase Series A-4, upon conversion to common warrants		—		1,836,429
Issuances upon exercise of common stock warrants		24,333,365		1,353,062
Earnout shares		23,482,845		—
Total common stock reserved for future issuance		68,233,622		65,242,854

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~NOTE 10. FAIR VALUE MEASUREMENTS~~

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2021 and December 31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

Description

Level

September 30, 2021

December 31, 2020
Assets:






Cash and marketable securities held in Trust Account

1

$
276,178,675

$
276,209,453

Liabilities:






Warrant Liability – Public Warrants

1

$
12,006,000

$
19,458,000
Warrant Liability – Private Placement Warrants

3

$
20,380,148

$
10,643,808

~~The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant~~long-term liabilities in the accompanying condensed consolidated balance ~~sheets.~~sheets at March 31, 2022 and December 31, 2021, respectively. In October 2021, the Italian federal tax authority initiated an audit of the research and development tax credits for the calendar years 2017 through 2019. The ~~warrant liabilities are measured~~Company expects that this tax audit will continue through 2022.

Litigation

In connection with the Business Combination, the Company received a litigation demand letter from certain purported stockholders alleging that the Company was required to provide holders of Class A Common Stock a separate class vote in connection with

proposed amendments of the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares, such that separate votes can be cast on the proposed increase in the number of shares of Class A common stock and the proposed increase in the number of shares of preferred stock. While the Company believes that the ultimate outcome of this litigation demand will not have a material effect on these condensed consolidated financial statements as well as its financial position, results of operations, and cash flows, the Company is unable to determine a range of potential losses that is reasonably possible of occurring.

20.

Related Party Transactions

The Company had the following transactions with related parties:

PureTech

In June 2019, PureTech executed a sublease agreement with the Company (see Note 19). With respect to the sublease, the Company incurred lease expense of $0.1 million and $0.2 million during three months ended March 31, 2022 and 2021, respectively, recorded in general and administrative expenses in the accompanying condensed consolidated statements of operations. The Company incurred royalty expense of $0.2 million and less than $0.1 million in connection with the PureTech royalty agreement (see Note 19) during the three months ended March 31, 2022 and 2021, respectively, recorded in cost of goods sold in the accompanying condensed consolidated statements of operations. The Company had an accounts payable balance to PureTech of $0.3 million and $0.1 million at March 31, 2022 and December 31, 2021, respectively, in the accompanying condensed consolidated balance sheets.

On December 13, 2021, the Company issued a convertible promissory note to PureTech in the principal amount of $15.0 million (see Note 12). At December 31, 2021, the outstanding balance was $15.1 million, recorded at fair value ~~at inception and on~~in the accompanying condensed consolidated balance sheets. On January 19, 2022 the Company settled the convertible promissory notes in cash for principal plus accrued interest in the aggregate amount of $15.2 million. During the three months ended March 31, 2022, the Company recognized a ~~recurring basis,~~loss of $0.1 million with ~~changes in fair value presented within~~respect to the change in fair value of ~~warrant liabilities in~~ the convertible promissory notes on the accompanying condensed consolidated statements of operations.

~~Level 3 financial liabilities consist~~SSD2

On December 13, 2021, the Company issued a convertible promissory note to SSD2, LLC in the principal amount of $12.0 million (see Note 12). At December 31, 2021, the ~~Private Placement Warrant liability for which there is no current market for these securities such that the determination of~~outstanding balance was $12.1 million, recorded at fair value ~~requires significant judgment or estimation. Changes~~ in ~~fair value measurements categorized within Level 3~~the accompanying condensed consolidated balance sheets. On January 19, 2022 the Company settled the convertible promissory notes in cash for principal plus accrued interest in the aggregate amount of $12.1 million. During the ~~fair value hierarchy are analyzed each period based on changes~~three months ended March 31, 2022, the Company recognized a loss of less than $0.1 million with respect to the change in ~~estimates or assumptions and recorded as appropriate.~~

~~The~~ fair value of the ~~Private Placement Warrants was estimated~~convertible promissory notes on the accompanying condensed consolidated statements of operations.

One S.r.l

Consulting Agreement with Founder of One

The Company and one of the founders of One, who is also a stockholder of the Company, entered into a consulting agreement for the development of the Company's science and technology. The Company incurred costs for consulting services received from the founder of One totaling less than $0.1 million during each of the three months ended March 31, 2022 and 2021, respectively, recorded in research and development expense in the accompanying condensed consolidated statements of operations. The Company recorded an accounts payable balance to the founder of less than $0.1 million at ~~September 30, 2021~~both March 31, 2022 and December 31, ~~2020~~2021, respectively, in the accompanying condensed consolidated balance sheets.

Acquisition of One

In connection with the amended and restated master agreement with One (see Note 11), the Company acquired a 10.0% equity interest in One in exchange for cash consideration. During the three months ended March 31, 2022 the Company made a payment of $2.9 million to One shareholders with respect to the acquisition. The Company had remaining undiscounted payments of €2.5 million and €5.0 million due to one at March 31, 2022 and December 31, 2021, respectively (approximately $2.8 million and $5.7 million due to One at March 31, 2022 and December 31, 2021, respectively). The balance at March 31, 2022 was recorded in accrued expenses in the accompanying condensed consolidated balance sheets as it is expected to be ~~$2.71 per warrant~~settled within the next twelve months.

Additionally, the Company incurred royalty expense of $0.2 million and ~~$1.42 per warrant, respectively, using the modified Black-Scholes option pricing model and the following assumptions:~~

September 30,

December 31,

2021

2020

Risk-free interest rate

1.02
%

0.47
%
Expected Term

5.25

5.76

Dividend yield

0.00
%

0.00
%
Expected volatility

13.5
%

19.0
%
Exercise price

$
11.50

$
11.50

Unit Price

$
9.92

$
10.15

$0.1

~~The following table presents the changes in the fair value of Level 3 warrant liabilities:~~

Private Placement
Fair value as of December 31, 2020

$
10,643,808
Change in fair value

(5,273,024)
Fair value as of March 31, 2021

5,370,784
Change in fair value

1,422,600
Fair value as of June 30, 2021

6,793,384
Change in fair value

13,586,764
Fair value as of September 30, 2021

20,380,148

~~There were 0 transfers in or out of Level 3 from other levels in the fair value hierarchy~~ million with One (see Note 19) during the three ~~and nine~~ months ended ~~September 30, 2021.~~

March 31, 2022 and 2021, respectively, recorded in cost of goods sold in the accompanying condensed consolidated statements of operations. The Company had an accounts payable balance to One Srl of less than $0.1 million and an accrued expense balance of $0.2 million at March 31, 2022 and an accrued expense balance of less than $0.1 million at December 31, 2021, respectively, related to royalties in the accompanying condensed consolidated balance sheets.

RIF Transaction

In connection with the RIF transaction entered into in August 2020, the Company received $12.3 million from RIF as an equity investment that can be called by the Company beginning in December 2023 and ending in December 2026 by paying the investment

plus 15.0% percent annual interest or put by RIF starting in January 2027 and ending in December 2027 for the investment amount plus 3.175% percent annual interest. RIF holds approximately 20% of the equity of Gelesis S.r.l. at December 31, 2021 (see Note 11). In addition, the shareholders of RIF provided the Company with a loan for $18.4 million with a fixed interest rate of 6.35% per annum (see Note 12).

21.

Subsequent Event(s)

~~Table of Contents~~

~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~

~~NOTES TO CONDENSED~~~~CONSOLIDATED FINANCIAL STATEMENTS~~

~~SEPTEMBER 30, 2021~~

~~(Unaudited)~~

~~NOTE 11. SUBSEQUENT EVENTS~~

The Company has evaluated subsequent events ~~and transactions that occurred after the balance sheet date up~~which may require adjustment to the date that the condensed consolidated financial statements were issued. Based upon this review, other than the below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed consolidated financial ~~statements.~~

~~As described in Note 7,~~statements through the ~~Company entered into a Business Combination Agreement on July 19, 2021~~date of issuance of these condensed consolidated financial statements and entered into a Business Combination Agreement Amendment on November 8, 2021. In connection, and concurrently, with the execution of the Business Combination Agreement Amendment, Capstar, Capstar Sponsor Group LLC (the “Sponsor”), certain affiliates of the Sponsor and Gelesis entered into an amendment to that certain Sponsor Letter Agreement, dated July 19, 2021.concluded there are none.

~~Table of Contents~~

~~ITEM~~

Item 2. ~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~Management’s Discussion and Analysis of Financial Condition and Results of Operations

References ~~in this report (the “Quarterly Report”)~~ to the “Company,” “our,” “us,” “we,” ~~“us”~~ or ~~the “Company”~~“Gelesis” refer to Gelesis Holdings, Inc. and its consolidated subsidiaries (formerly known as Capstar Special Purpose Acquisition Corp. ~~References to our “management”~~ or ~~our “management team” refer to our officers and directors, references to~~"CPSR") following the ~~“Sponsor” refer to Capstar Sponsor Group, LLC.~~Business Combination with Gelesis Inc., or Legacy Gelesis. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with (i) the condensed consolidated financial statements and the notes thereto contained elsewhere in this Quarterly ~~Report.~~Report and (ii) the audited historical consolidated financial statements of Legacy Gelesis, and the notes thereto, in our Form 8-K Amendment No. 1 filed on with the SEC on March 24, 2022. Certain of the information contained in ~~the~~this discussion and analysis or set forth ~~below~~elsewhere in this Quarterly Report, including information with respect to plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties.

~~Special~~ As a result of many factors, including, but not limited to, those set forth in the section entitled “Cautionary Note Regarding Forward-Looking ~~Statements~~

~~This~~Statements” in this Quarterly Report ~~includes “forward-looking statements” within~~and those set forth in the ~~meaning~~section entitled “Risk Factors” in Item 1A of ~~Section 27A~~Part II of this Quarterly Report and in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on April 1, 2022, or our 2021 Annual Report, actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date hereof or to conform these statements to actual results or revised expectations. You should carefully read the sections entitled “Cautionary Note Regarding Forward-Looking Statements” in this Quarterly Report and “Risk Factors” in Item 1A of Part II of this Quarterly Report and in Item 1A of Part 1 of our 2021 Annual Report to gain an understanding of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are not historical facts, and involve risks and uncertaintiesimportant factors that could cause actual results to differ materially from our forward-looking statements.

Overview

We are a commercial stage biotherapeutics company built for consumer engagement. We are focused on advancing first-in-class superabsorbent hydrogel therapeutics for chronic gastrointestinal, or GI, diseases including excess weight, type 2 diabetes, NAFLD/NASH, functional constipation, and inflammatory bowel disease. Our biomimetic superabsorbent hydrogels are inspired by the composition and mechanical properties (e.g. firmness) of raw vegetables. They are conveniently administered in capsules taken with water to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system.

Our first commercial product, Plenity, received de novo clearance from the FDA on April 12, 2019 to aid in weight management in adults with excess weight or obesity, Body Mass Index (BMI) of 25 to 40 kg/m2, when used in conjunction with diet and exercise.

Plenity, which is available by prescription in the United States, became available for first commercial sale in May 2020 to a limited number of consumers. In October 2020 availability was increased to test commercial interest and consumer experience. Activities associated with a full commercial launch in the United States began in late 2021, and in February 2022, we launched the first national broad awareness media campaign for the product. While these are significant milestones, continued commercialization of Plenity will require significant external funding until we are able to generate positive cash flows from product sales.

Since our inception, we have devoted our resources to business planning, developing proprietary superabsorbent hydrogel manufacturing know-hows and technologies, preclinical and clinical development, commercial activities, recruiting management and technical staff and raising capital. We have funded our operations to date through proceeds from the issuance of redeemable convertible preferred stock, license and collaboration agreements, long-term loans, and government grants. We have incurred significant operating losses to date. Our net losses were $5.7 million and $18.6 million for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, we had an accumulated deficit of $271.3 million. We expect to continue to generate operating losses and negative operating cash flows for the foreseeable future.

As a result, we will require substantial additional funding to support our continuing operations until we are able to generate positive cash flows from product sales. Until such time, we expect to finance our operations through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If we are unable to obtain funding, we may be forced to delay, reduce or eliminate some or all of our commercialization efforts, research and development programs or product pipeline expansion, which could adversely affect our business prospects, or we may be unable to continue operations.

As of the date of this Quarterly Report, we expect that our existing cash and cash equivalents will only be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2023, prior to considerations for any additional funding, and not at least twelve months beyond the date of issuance of the unaudited condensed consolidated financial statements

included elsewhere in this Quarterly Report. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern. Our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report, which have been prepared in accordance with GAAP, contemplate that we will continue to operate as a going concern. Our financial statements do not contain any adjustments that might result if we are unable to continue as a going concern. See “—Liquidity and Capital Resources” for further information.

Recent Developments

Launch of Broad Consumer Awareness Campaign

On January 31, 2022, we debuted our broad consumer awareness campaign which included TV, digital, social, and Out of Home media channels to grow awareness of Plenity. Following the launch of the campaign:

•

we acquired approximately 4,700 new members per week, a 3.5-fold increase, within the first three weeks of the launch, compared to the previous months before campaign launch;

•

within the first two weeks of campaign launch, Plenity became one of our telehealth partner Roman Health Pharmacy LLC’s (“Ro’s”) most sought-after offerings and Ro’s fastest growing offering, bringing on more new consumers than any other treatment or product during the period;

•

traditional physician prescriptions of Plenity increased 100% within the first three weeks of campaign launch and over 40% of those treatment requests were driven by the consumer (a 60% increase from the pre-campaign baseline); and

•

our digitally native platform enables live results, and within seconds of launching the campaign search interest and website traffic increased significantly, scaling from seven to ten thousand visitors per day prior to the campaign to between thirty to forty thousand website visitors per day.

Following the success of the initial wave of this campaign, we are evaluating optimal media channels, timing, pulse frequency, and investment levels going forward.

Impact of COVID-19

In December 2019, illnesses associated with COVID-19 were reported and the virus has since caused widespread and significant disruption to daily life and economies across geographies. The World Health Organization has classified the outbreak as a pandemic. Our business, operations and financial condition and results have not been significantly impacted as a result of the COVID-19 pandemic, rather we have recognized revenue for the first time during 2020 and we have expanded our facilities, sales/marketing and supply chain personnel to support the sale of Plenity. To date, COVID-19 has not materially impacted our ability to secure and deliver supply of Plenity. To date, COVID-19 has not significantly impacted ongoing clinical trials of our other product candidates.

In response to the COVID-19 pandemic, we have taken swift action to ensure the safety of our employees and other stakeholders. We are diligently working with our suppliers, customers, distributors and other partners to provide consumers with access to Plenity, while taking into account regulatory, institutional, and government guidance, policies and protocols.

However, the full extent of the impact of the pandemic and future outbreaks on our business, operations, and financial condition and results in future periods remain uncertain, particularly, with respect to consumer demand for or access to Plenity, and the administration of clinical research and development activities. Further, our ability to source raw materials and components, manufacture Plenity as well as transport and distribute Plenity may be limited and therefore impact sales of Plenity.

Key Factors Affecting Results of Operations

We believe that our performance and future success depend on several factors that present not only significant opportunities for us but also pose risks and challenges, including those discussed below.

New Consumer Acquisition

Our ability to attract new consumers is a key factor for our future growth. To date we have successfully acquired consumers through our U.S. commercial launch in conjunction with the continued development of marketing and sales tactics. We intend to acquire new

members in the United States by promoting Plenity directly to the consumer. The promotional activities will motivate the potential future member to ask a health care professional about acquiring Plenity through one of two channels:

•

Telehealth: We partner with a leading telehealth platform in the United States, providing convenient and immediate access to physicians online at no cost. Pursuant to an amended and restatement agreement, we have granted Roman Health Pharmacy LLC exclusive telehealth rights through June 2023.

•

Health Care Providers: We engage a limited contract sales force to promote Plenity to target physicians. To support prescription fulfillment for our non-telehealth tradition HCP promotional efforts, we engage Specialty Medical Drugstore, LLC, d/b/a/ GoGoMeds, to distribute all non-telehealth mail order prescriptions generated in the United States by health care providers.

Retention of Consumers

Our ability to retain consumers is a key factor in our ability to generate revenue. We expect our direct home delivery, simple and transparent pricing, and consumer engagement to enhance the experience of our consumer and promote recurring revenue. If consumer retention decreases in the future, then future revenue will be negatively impacted. The ability of our consumers to continue to pay for our products and services will also impact the future results of our operations.

Rest of World

We are evaluating global strategic partnerships to build our brand globally; however, we may also retain the rights.

•

Europe: We received approval to market Plenity in Europe through a Conformité Européenne (CE) mark for Plenity as a class III medical device indicated for weight loss in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m2, when used in conjunction with diet and exercise.

•

CMS: In Greater China (including Mainland China, Hong Kong, Macau, and Taiwan), Singapore and United Arab Emirates, we partner with China Medical System Holdings Limited (CMS) (HKG:0867) for the commercialization of Plenity.

Investments in Growth

We expect to make significant investments in selling and marketing to acquire new consumers. Selling and marketing is an important driver of growth, and we intend to continue to make significant investments in consumer acquisition and our selling and commercial infrastructure. As such, we expect our selling and marketing expense to increase in absolute dollars in the short term. However, we expect our selling and marketing expense to decrease as a percentage of revenue over the long term, although our selling and marketing expense may fluctuate as a percentage of revenue from period to period due to the timing and amount of these expenses.

Additionally, we intend to continue to invest significantly in our manufacturing, fulfillment and operating capabilities. In the short term, we expect these investments to increase our operating expenses; however, in the long term we anticipate that these investments will positively impact our results of operations. If we are unable to generate sufficient demand in Plenity, we may not have sufficient funds to investment into these growth activities.

Product Candidate Expansion

In addition to Plenity, we have invested in a pipeline of product candidates for prevalent and important gastrointestinal, or GI, tract-related chronic diseases including, type 2 diabetes, NAFLD/NASH, chronic idiopathic constipation, and inflammatory bowel disease by targeting the natural processes of the GI pathway. We expect to continue investing in our pipeline over time to broaden our commercial opportunity. The continued preclinical and clinical development of the pipeline will require significant financial resources. If we are unable to generate sufficient demand in Plenity or raise additional capital at favorable terms, if at all, we may not have sufficient funds to invest in the research and development of additional product candidates.

Key Business Metrics

We monitor the following key metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following metrics are useful in evaluating our business (dollar amounts in thousands except where noted):


	For the Three Months Ended March 31,
	2022			2021
In thousands	(Unaudited)			(Unaudited)
New members acquired		40,400			14,100
Units sold		114,570			48,761
Product revenue, net	$	7,514		$	3,101
Average selling price per unit, net	$	65.58		$	63.60
Gross profit	$	2,601		$	285
Gross margin		34.6	%		9.2	%

New members acquired

We define new members acquired as the number of consumers in the United States who have begun their weight loss journey with Plenity during the financial period presented. This is the total number of recurring and non-recurring consumers who have begun their weight loss journey during the financial period presented. We do not differentiate from recurring and non-recurring consumers as of the date of this Quarterly Report as (i) we strongly believe every member’s weight-loss journey is chronic and long-term in nature, and (ii) we have not initiated our long-term strategy and mechanisms to retain and/or win-back members. We will continue to evaluate the utility of this business metric in future periods.

Units sold

Units sold is defined as the number of 28-day supply units of Plenity sold to consumers based on prescriptions, through our strategic partnerships with online pharmacies and telehealth providers as well as the units sold to our strategic partners outside the United States.

Product revenue, net

See discussion elsewhere in this discussion and analysis under the heading “Key Components of Results of Operations — Product revenue, net”.

Average selling price per unit, net

Average selling price per unit, net is the gross price per unit sold during the period net of estimates of per unit variable consideration for which reserves are established for expected product returns, shipping charges to end-users, pharmacy dispensing and ~~projected. All~~platform fees, merchant and processing fees, and promotional discounts offered to end-users. See “— Critical Accounting Policies and Significant Judgments and Estimates” below and the “Revenue Recognition” section of Note 2 in the accompanying Notes to unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for a more detailed discussion of our revenue recognition policy.

Gross profit and gross margin

Our gross profit represents product revenue, net, less our total cost of goods sold, and our gross margin is our gross profit expressed as a percentage of our product revenue, net. See discussion elsewhere in this discussion and analysis under the headings “Key Components of Results of Operations — Cost of goods sold”.

Our gross profit and gross margin have been and will continue to be affected by a number of factors, including the prices we charge for our product, the costs we incur from our vendors for certain components of our cost of goods sold, the mix of channel sales in a period, and our ability to sell our inventory. We expect our gross margin to increase over the long term, although gross margins may fluctuate from period to period depending on these and other ~~than~~factors.

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with GAAP, we believe the following non-GAAP measure is useful in evaluating our operating performance. We use the following non-GAAP financial measure to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measure, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures

differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for the non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measure and the reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. We define “Adjusted EBITDA” as net (loss) income before depreciation and amortization expenses, provision for (benefit from) income taxes, interest expense, net, stock-based compensation and (gains) and losses related to changes in fair value of our earnout liability, fair value of our warrant liability, our convertible promissory note liability and the One S.r.l. call option.

The following table reconciles net loss to Adjusted EBITDA for the three months ended March 31, 2022 and 2021, respectively:


	For the Three Months Ended March 31,
	2022			2021
In thousands	(Unaudited)			(Unaudited)
Adjusted EBITDA
Net loss	$	(5,703	)	$	(18,586	)
Provision for income taxes		—			17
Depreciation and amortization		1,586			741
Stock based compensation expense		13,989			1,455
Change in fair value of earnout liability		(33,869	)		—
Change in fair value of warrants		(3,484	)		2,074
Change in fair value of convertible promissory notes		156			—
Change in fair value of One S.r.l. call option		258			48
Interest expense, net		135			361
Adjusted EBITDA	$	(26,932	)	$	(13,890	)

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

Basis of Presentation

Our consolidated financial statements and condensed consolidated financial statements are prepared in accordance with GAAP. Any reference in this discussion and analysis to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”).

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. We view our operations and manage our business as one operating segment.

The noncontrolling interest attributable to Gelesis S.r.l., our variable interest entity (“VIE”), is presented as a separate component from stockholders’ equity (deficit) in our consolidated balance sheets and as a noncontrolling interest in our condensed consolidated statements of ~~historical fact~~noncontrolling interest, redeemable convertible preferred stock and stockholders’ equity. All intercompany balances and transactions have been eliminated in consolidation.

Key Components of Results of Operations

Product revenue, net

We recognize product revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, when we transfer promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

Our product revenue is derived from product sales of Plenity, net of estimates of variable consideration for which reserves are established for expected product returns, shipping charges to end-users, pharmacy dispensing and platform fees, merchant and processing fees, and promotional discounts offered to end-users.

Cost of goods sold

Cost of goods sold includes the cost of manufacturing our proprietary superabsorbent hydrogels for Plenity for which revenue was recognized during the period, as well as the associated costs for encapsulation, packaging, shipment, supply management and quality assurance. Expenses from royalty agreements on net product sales are also recognized as a component of cost of goods sold during the period in which the associated revenues are recognized. A portion of depreciation with respect to property and equipment directly utilized in manufacturing Plenity units is recognized as a component of cost of goods sold over the depreciable life of the asset.

Selling, general and administrative expense

A significant component of our selling, general and administrative expenses is comprised of our selling and marketing expense, which includes our limited contract sales force in the US markets and discretionary consumer acquisition expenses.

Selling, general and administrative costs are expensed as incurred. Selling, general and administrative costs include sales and marketing costs incurred as a result of the commercialization of the Company’s products, payroll and personnel expense, stock-based compensation expense, and costs of programs and infrastructure necessary for the general conduct of the Company’s business.

Research and development expense

Research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period, as the services are provided. Research and development costs include payroll and personnel expense, stock-based compensation expense, consulting costs, external contract research and development expenses, as well as depreciation and utilities. These activities relate primarily to formulation, CMC, preclinical and discovery activities. As such, we do not track these research and development expenses on an indication-by-indication basis as they primarily relate to expenses which are deployed across multiple projects under development or are for future product and pipeline candidates which utilize our platform technology. These costs are included in ~~this Form 10-Q including, without limitation,~~unallocated research and development expenses in the tables below.

Clinical trial costs are a component of research and development expenses and consist of clinical trial and related clinical manufacturing costs, fees paid to clinical research organizations and investigative sites. We track and maintain these costs on an indication-by-indication basis.

Amortization expense

Amortization expense relates to the intangible asset that resulted from an amendment to our master agreement with the original inventor of our core patents, pursuant to which the percentage of royalties we are required to pay on future net revenues was reduced. The intangible asset is amortized over its useful life, which was determined as of the date of the amendment to be the earliest expiration of patents related to the underlying IP in November 2028.

Other non-operating income (expense), net

Change in the fair value of earnout liability

We have earnout shares which are contingent issuable as incremental consideration pursuant to ASC 815. The earnout shares are initially recorded at fair value and remeasured to fair value at each reporting date until settlement with gains and losses arising from changes in fair value recognized in the consolidated statements of operations.

Changes in the fair value of warrants

We have issued warrants to investors which are liability classified and initially recorded at fair value and remeasured to fair value at each reporting date until settlement with gains and losses arising from changes in fair value recognized in the consolidated statements of operations.

Interest expense, net

Interest expense, net consists of interest incurred on our various loans and interest income earned on our cash, cash equivalents and marketable securities.

Other income (expense), net

Other income, net primarily consists of income earned on our grants from government agencies in Italy, research and development tax credits earned in Italy for qualifying expenses, and gains and losses on foreign currency transactions. Other income, net also consists of changes in fair value of the One Srl call option.

Provision for income taxes

We must make certain estimates and judgments in determining income tax expense for financial statement purposes. The amount of taxes currently payable or refundable is accrued, and deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities and their respective tax bases. Deferred tax assets are also recognized for realizable loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using substantively enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Net deferred tax assets are not recorded if we do not assess their realization as probable. The effect on deferred tax assets and liabilities of a change in income tax rates is recognized in our financial statements in the period that includes the substantive enactment date.

Results of Operations

Comparison of the Three Months Ended March 31, 2022 and March 31, 2021:

The following table summarizes our results of operations:


	For the Three Months Ended March 31,						Increase
	2022			2021			(Decrease)
	(Unaudited)			(Unaudited)
Revenue:
Product revenue, net	$	7,514		$	3,101		$	4,413
Total revenue, net		7,514			3,101			4,413
Operating expenses:
Costs of goods sold		4,913			2,816			2,097
Selling, general and administrative		37,706			11,945			25,761
Research and development		7,410			4,376			3,034
Amortization of intangible assets		567			567			—
Total operating expenses		50,596			19,704			30,892
Loss from operations		(43,082	)		(16,603	)		(26,479	)
Other non-operating income (expense), net		37,379			(1,966	)		39,345
Loss before income taxes		(5,703	)		(18,569	)		12,866
Provision for income taxes		—			17			(17	)
Net loss	$	(5,703	)	$	(18,586	)	$	12,883

Product revenue, net

We recognized product revenue, net of $7.5 million for the three months ended March 31, 2022, as compared to $3.1 million for the three months ended March 31, 2021, an increase of $4.4 million or 142%. We sold 114,570 units at an average selling price per unit, net of $65.58 for the three months ended March 31, 2022, as compared to 48,761 units at an average selling price per unit, net of $63.60 for the three months ended March 31, 2021.

The increase in units sold was primarily attributable to our planned and executed commercialization strategy for Plenity. We made Plenity available for commercial sale through a beta launch that began in in October 2020 and continued throughout 2021. Activities associated with a full commercial launch of the Product in the United States began in late 2021, and in February 2022, we launched the first national broad awareness media campaign for Plenity.

Cost of goods sold

We recognized cost of goods sold of $4.9 million for the three months ended March 31, 2022, as compared to $2.8 million for the three months ended March 31, 2021, an increase of $2.1 million. Depreciation as a component of cost of goods sold was $0.7 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively. The increases were primarily attributable to the revenue recognized with respect to units sold for the three months ended March 31, 2022, as compared to the three months ended March 31, 2021.

Gross profit was $2.6 million for the three months ended March 31, 2022, as compared to $0.3 million for the three months ended March 31, 2021. Gross margin also increased to 34.6% for the three months ended March 31, 2022, as compared to 9.2% for the three

months ended March 31, 2021. The increases were primarily attributable to production commencing at our first commercial-scale manufacturing facility in the fourth quarter of 2021 and the implementation of new finished-goods packaging in the third quarter 2021.

Selling, general and administrative expense

The following table summarizes our selling, general and administrative expenses for the three months ended March 31, 2022 and 2021:


	For the Three Months Ended March 31,				Increase
	2022		2021		(Decrease)
In thousands	(Unaudited)		(Unaudited)
Selling and marketing expense	$	21,164	$	7,686	$	13,478
General and administrative expense		7,618		3,371		4,247
Non-cash stock-based compensation expense		8,924		888		8,036
Total selling, general and administrative expense	$	37,706	$	11,945	$	25,761

Our selling, general and administrative expense was $37.7 million for the three months ended March 31, 2022, as compared to $11.9 million for the three months ended March 31, 2021, an increase of $25.8 million or 216%.

Selling and marketing expense increased $13.5 million for the three months ended March 31, 2022, as compared to the three months ended March 31, 2021. The increase in selling and marketing expense was primarily attributable to increased marketing spend to support the commercial sale of Plenity. In February 2022, we launched the first national broad awareness media campaign for the product, which included TV, digital, social, and Out of Home media channels to grow awareness of Plenity.

Non-cash stock-based compensation expense increased $8.0 million for the three months ended March 31, 2022, as compared to the three months ended March 31, 2021. The increase was primarily attributable to the incremental compensation cost with respect to contingently issuable earnout shares pertaining to Legacy Gelesis equity awards, which had previously vested.

General and administrative expense increased $4.2 million for the three months ended March 31, 2022, as compared to the three months ended March 31, 2021. The increase was primarily attributable to professional and legal expenses incurred with respect to the Business Combination.

Research and development expenses

The following table summarizes our research and development expenses for the three months ended March 31, 2022 and 2021:


	For the Three Months Ended March 31,				Increase
	2022		2021		(Decrease)
In thousands	(Unaudited)		(Unaudited)
GS200	$	7	$	794		(788	)
GS300		136		—		136
GS500		75		—		75
Unallocated expenses
Other research and development expenses		2,127		3,015		(888	)
Non-cash stock-based compensation expense		5,065		567		4,498
Total Research and development expense	$	7,410	$	4,376	$	3,034

Our research and development expense was $7.4 million for the three months ended March 31, 2022, as compared to $4.4 million for the three months ended March 31, 2021, an increase of $3.0 million, or 69%.

Non-cash stock-based compensation expense increased $4.5 million for the three months ended March 31, 2022, as compared to the three months ended March 31, 2021. The increase was primarily attributable to the incremental compensation cost with respect to contingently issuable earnout shares pertaining to Legacy Gelesis equity awards, which had previously vested.

The decline in research and development expenses within clinical indications (GS200, GS300 and GS500) was primarily attributable to the conclusion of the LIGHT-UP study with respect to GS200 during the year ended December 31, 2021, as well as the strategic prioritization of the commercialization of Plenity particularly with respect to our financial and human resources. Similarly, other

research and development expenses declined $0.9 million for the three months ended March 31, 2022, as compared to the three months ended March 31, 2021.

Other non-operating income (expense), net

We recognized other non-operating income, net of $37.4 million for the three months ended March 31, 2022, as compared to expense, net of $1.9 million for the three months ended March 31, 2021, an increase in income of $39.3 million. The income for the three months ended March 31, 2022 was primarily attributable to income of $33.9 with respect to the change in fair value of our earnout liability as well as income of $3.5 million with respect to the change in fair value of our warrant liabilities. The income for the three months ended March 31, 2022, was further attributable to $0.3 million in investment tax credit income recognized with respect to certain tax incentives offered for property and equipment investment in Italy and income of $0.4 million recognized with respect to grants awarded by the Puglia region of Italy. The income was partially offset by a loss of $0.3 million recognized with respect to the change in fair value of the One S.r.l. call option.

The expense for the three months ended March 31, 2021 was primarily attributable to a loss of $2.1 million recognized for the change in fair value of our warrant liabilities.

Liquidity and Capital Resources

Since inception, we have financed our operations primarily from the issuance of equity and debt instruments, license and collaboration agreements, supply and distribution agreements, and government grants. As of March 31, 2022, our principal sources of liquidity were our cash and cash equivalents in the amount of $34.0 million. During the three months ended March 31, 2022, we closed a business combination with CPSR, pursuant to which we received $105.0 million in gross proceeds, prior to the payment of transactions fees due and payable. As of the date of this Quarterly Report, we expect that our existing cash and cash equivalents will only be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2023.

Due to our available cash and cash equivalents, a history of recurring losses from operations, negative cash flows from operations, and a significant accumulated deficit, we have concluded that there is substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm included an emphasis of matter paragraph in their opinion for the years ended December 31, 2021 and 2020, respectively, as to the substantial doubt about our ability to continue as a going concern. Our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report, which have been prepared in accordance with GAAP, contemplate that we will continue to operate as a going concern. Our financial statements do not contain any adjustments that might result if we are unable to continue as a going concern.

We have incurred negative cash flows from operating activities and significant losses from operations in the past. We expect to continue to incur operating losses for at least the next twelve months due to the investments that we intend to make in our business to support the commercialization of Plenity and, as a result, we will require additional capital resources to grow our business.

Future Liquidity Requirements

Prior to the closing of the Business Combination, holders of 26,844,777 shares of CPSR Class A Common Stock exercised their right to redeem such shares for cash at a price of approximately $10.00 per share for aggregate payments of $268,646,943. As a result, upon closing of the Business Combination, we received approximately $105.0 million of gross proceeds to fund our future capital and liquidity needs. Due to the significant number of redemptions, we implemented an alternative business plan, prioritizing short-term working capital needs such as investments in raw materials and finished goods as well as investments in sales and marketing, and delaying certain long-term capital expenditures in commercial infrastructure and certain research and development expenses. We reduced and optimized investments in sales and marketing, prioritizing investments in high return and high exposure mediums. We have sought out, and continue to seek out, alternative commercial arrangements or geographic distribution partnerships to finance certain investments in sales and marketing associated with the sale of Plenity. We expect these actions will provide us with sufficient liquidity to manage short-term risk and uncertainty and (i) enable us to execute our alternative business plan, (ii) afford us time to access financing alternatives to provide for long-term liquidity and (iii) enable us to fund the continued commercialization of Plenity. See Part I, Item 1A, “Risk Factors — There were a significant number of redemptions in connection with the Business Combination and if we are not successful in implementing an alternative business plan and/or raising additional capital in a timely manner, we may have insufficient cash and liquidity to pay operating expenses and other obligations. Any such event would have a material adverse effect on our business and financial condition.” in our 2021 Annual Report for more information regarding the risk associated with our ability to implement our business plan and/or raise additional capital.

As a result, even with proceeds from the Business Combination, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through issuance of additional equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions.

As of the date of this Quarterly Report, we are continuing to evaluate opportunities to raise additional capital. If we are unsuccessful in raising additional capital, we may need to further restrict our spending particularly with respect to discretionary sales and marketing activities and our manufacturing and supply chain functions. Further changes to the execution of our alternative business plan may impact the growth of Plenity sales and the pace of acquisition and retention of consumers, as well as the price of our common stock.

Revenue Projections

Our revenue projections are highly dependent on (i) our ability to acquire new consumers and/or retain existing consumers and (ii) our ability to access additional capital and raise sufficient levels of funding in a timely manner to support the sales and marketing of Plenity at a broad national level within the United States. If our access to additional capital is delayed or insufficient, it may adversely impact the sale of Plenity and our revenue projections. See Part II, Item 1A “Risk Factors – The financial and operational projections and commercialization and product candidate development timelines that we may provide from time to time are subject to inherent risks.” in this Quarterly Report for more information.

Warrant Proceeds

As of the date of this Quarterly Report, we have 13,800,000 outstanding Public Warrants to purchase 13,800,000 shares of our common stock, exercisable at an exercise price of $11.50 per share, which expire on the earlier to occur of January 13, 2027 or redemption; (ii) 7,520,000 outstanding Private Warrants to purchase 7,520,000 shares of our common stock, exercisable at an exercise price of $11.50 per share, which expire January 13, 2027 or redemption and (iii) 3,013,365 exercisable Rollover Warrants, 1,353,062 of which are exercisable at an exercise price of $4.26 and expire on October 21, 2030 and 1,660,303 of which are exercisable at an exercise price of $0.02 and expire on February 15, 2025.

The exercise of warrants is highly dependent on the price of our common stock and the spread between the exercise price of the warrant and the price of our common stock at the time of exercise. For example, to the extent that the price of our common stock exceeds $11.50 per share, it is more likely that holders of our Public Warrants and Private Warrants will exercise their warrants. To the extent that the price of our common stock is less than $11.50 per share, it is less likely that such holders will exercise their warrants. As of May 11, 2022, the price of our common stock price was $4.53 per share. There can be no assurance that our warrants will be in the money prior to their expiration and, as such, any or all of our warrants may expire worthless. Our Public Warrants under certain conditions, as described in the warrant agreement, are redeemable by the Company at a price of $0.01 per warrant or on a cashless basis. Our Private Warrants are not redeemable so long as they are held by the initial stockholders and are exercisable on a cashless basis. Our Rollover Warrants are not redeemable and are exercisable on a cashless basis only with respect to the 1,660,303 warrants that have an exercise price of $0.02. As such, it is possible that we may never generate any cash proceeds from the exercise of our warrants. As of the date of this Quarterly Report, we have neither included nor intend to include any potential cash proceeds from the exercise of our warrants in our short-term or long-term liquidity projections. We will continue evaluate the probability of warrant exercise over the life of our warrants and the merit of including potential cash proceeds from the exercise thereof in our liquidity projections.

To the extent such warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to the holders of our common stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could adversely affect the market price of our common stock, which increase the likelihood that our warrants will not be in the money prior to their expiration.

Financing Risk

We expect to devote significant efforts to raise capital, restructure our indebtedness and identify and evaluate potential strategic alternatives, however, there can be no assurance that we will be successful in obtaining capital sufficient to meet our operating needs on terms or a timeframe acceptable to us or at all. Further, in the event that market conditions preclude our ability to consummate such a transaction, we may be required to evaluate additional alternatives in restructuring our business and our capital structure. Any failure in these efforts could force us to delay, limit or terminate our operations, make reductions in our workforce, discontinue our commercialization efforts for Plenity as well as other development programs, liquidate all or a portion of our assets or pursue other strategic alternatives, and/or seek protection under the provisions of the U.S. Bankruptcy Code.

Although we have estimated our liquidity requirements based on assumptions we consider to be reasonable, we may need additional cash resources due to changed business conditions or other developments, including supply chain challenges, disruptions due to COVID-19, competitive pressures, and regulatory developments, among other developments. Our budget projections may be subject to cost overruns for reasons outside of our control and Plenity may experience slower sales growth than anticipated, which would pose a risk to achieve positive cash flow.

Our future capital requirements will depend on many factors, including increases in sales of Plenity, increases in our customer base, the timing and extent of spend to support the expansion of sales, marketing and development activities, and the impact of the COVID-19 pandemic. We may in the future also enter into arrangements to acquire or invest in complementary businesses, services and technologies, including intellectual property rights.

We have based our estimate of liquidity on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Our cash flows may fluctuate and are difficult to forecast and will depend on many factors mentioned elsewhere in this discussion and analysis. If we require additional equity or debt financing from outside sources, we may not be able to raise it on terms acceptable to us, or at all, and the Company may pursue financing transactions that are not completed. If we are unable to raise additional capital when desired, our business, financial condition and results of operations would be harmed.

Cash flows

The following table summarizes our cash flows for each of the periods presented:


	For the Three Months Ended March 31,
	2022			2021
In thousands	(Unaudited)			(Unaudited)
Cash (used in) provided by:
Operating activities	$	(35,183	)	$	(8,294	)
Investing activities		(1,963	)		17,646
Financing activities		42,780			3,334
Effect of exchange rates on cash		(46	)		(973	)
Increase in cash and cash equivalents	$	5,588		$	11,713

Cash used in operating activities

Net cash used in operating activities was $35.2 million for the three months ended March 31, 2022, as compared to $8.3 million for the three months ended March 31, 2021. The increase in outflows was primarily attributable to our operating expenses increasing $30.9 million to $50.6 million for the three months ended March 31, 2022, as compared to $19.7 million for the three months ended March 31, 2021.

Cash (used in) provided by investing activities

Net cash used in investing activities was $2.0 million for the three months ended March 31, 2022, as compared to $17.6 million provided by investing activities for the three months ended March 31, 2021. The outflows were primarily attributable to $1.9 million in the purchase of property and equipment for the three months ended March 31, 2022. For the three months ended March 31, 2021, inflows were primarily attributable to $24.0 million in maturities of marketable securities, which were partially offset by a $6.4 million in the purchase of property and equipment for the three months ended March 31, 2021.

Cash provided by financing activities

Net cash provided by financing activities was $42.7 million for the three month ended March 31, 2022, as compared to $3.3 million for the three months ended March 31, 2021. The increase in inflows was primarily attributable to net proceeds of $70.5 million received from the completion of the Business Combination in January 2022, which was partially offset by our repayment of convertible promissory notes also in January 2022, totaling $27.3 million, as compared to net proceeds of $3.5 million from the issuance of loans in Italy for the three months ended March 31, 2021.

Contractual Obligations and Commitments

For the three months ended March 31, 2022, there were no material changes to our contractual obligations and commitments from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Contractual Obligations and Commitments” in our Form 8-K Amendment No. 1 filed with the SEC on March 24, 2022, except in January 2022, we settled convertible promissory notes in cash for principal plus accrued interest in the aggregate amount of $27.3

million. For further information on these lease amendments, please see Note 12 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report.

Off-Balance Sheet Arrangements

We currently do not have, and did not have during the periods presented, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Critical Accounting Policies and Significant Judgments and Estimates

For the three months ended March 31, 2022, there have been no material changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s Annual Report onour Form ~~10-KA~~8-K Amendment No. 1 filed with the ~~U.S. Securities and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed~~SEC on March 24, 2022 other than those described in Note 2 in the ~~EDGAR section~~accompanying Notes to unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see Note 2 in the accompanying Notes to unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report.

JOBS Act Accounting Election

Under Section 107(b) of the ~~SEC’s website at www.sec.gov. Except as expressly required by applicable securities law,~~Jumpstart Our Business Startups Act of 2012, or the ~~Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result~~JOBS Act, an “emerging growth company” can delay the adoption of new ~~information, future events~~ or ~~otherwise.~~

~~Overview~~

revised accounting standards until such time as those standards would apply to private companies. We have elected to avail ourselves of this exemption to delay adopting new or revised accounting standards until such time as those standards apply to private companies. However, where allowable we have early adopted certain standards as described in Note 2 of our consolidated financial statements. There are ~~a blank check~~other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an “emerging growth company, ~~formed under the laws~~” we are exempt from Sections 14A(a) and (b) of the ~~State~~Exchange Act which would otherwise require us to (1) submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay,” “say-on-frequency,” and “golden parachutes;” and (2) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of Delaware on February 14, 2020 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar Business Combination with one or more businesses. our chief executive officer’s compensation to our median employee compensation.

We also intend to ~~effectuate our Business Combination using cash~~rely on an exemption from the ~~proceeds~~rule requiring us to provide an auditor’s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the ~~Initial Public Offering and the sale of the Private Placement Warrants, our capital stock, debt or a combination of cash, stock and debt.~~

Sarbanes-Oxley Act. We ~~expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.~~

~~Recent Developments~~

~~On July 19, 2021, we entered into the Business Combination Agreement with Merger Sub and Gelesis., which was amended on November 8, 2021.~~

~~The Business Combination Agreement and the transactions contemplated thereby were approved by the board of directors of each of CPSR and Gelesis.~~

~~Table of Contents~~

In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the Effective Time, (i) each share of Gelesis outstanding as of immediately prior to the Effective Time will be exchanged for CPSR Shares based on an implied Gelesis equity value of $675,000,000, (ii) all vested and unvested stock options of Gelesis will be assumed by us and thereafter be settled or exercisable for CPSR Shares, as applicable, determined based on the same implied Gelesis equity value described in clause (i); (iii) each warrant of Gelesis will be canceled in exchange for a warrant to purchase our shares of determined based on the same implied Gelesis equity value described in clause (i); and (iv) each share of CPSR Class A common stock and each share of CPSR Class B common stock that is issued and outstanding immediately prior to the Effective Time shall become one CPSR Share following the consummation of the Business Combination. In addition, each holder of shares of Gelesis common stock, options and warrants will receive its pro rata portion of 23,483,250 restricted earn out CPSR Shares, which will vest (in part) in equal thirds if the trading price of CPSR Shares is greater than or equal to $12.50, $15.00 and $17.50, respectively, for any 20 trading days within any 30-trading day period on or prior to the date that is five years following the Effective Time (the “~~Earn Out Period~~~~”) and will also vest in connection with any Change of Control Transaction with respect to us if the applicable thresholds are met in such Change of Control Transaction during the Earn Out Period.~~

The Business Combination is expected to close in the fourth quarter of 2021, following the receipt of the required approval by our stockholders and the fulfillment of other customary closing conditions.

~~Results of Operations~~

We have neither engaged in any operations (other than searching for a Business Combination after our Initial Public Offering) nor generated any revenues to date. Our only activities through September 30, 2021 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, finding a target company for a Business Combination and activities in connection with the proposed acquisition of Gelesis. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended September 30, 2021, we had a net loss of $14,255,408, which consists of changes in fair value of warrant liabilities of $13,174,144, operating costs of $1,113,342, and an unrealized loss on marketable securities held in Trust Account of $106,039,offset by interest income on marketable securities held in the Trust Account of $138,117.

For the nine months ended September 30, 2021, we had a net loss of $3,657,398, which consists of changes in fair value of warrant liabilities of $2,284,340 and operating costs of $1,518,286, offset by an unrealized gain on marketable securities held in Trust Account of $2,231, and interest income on marketable securities held in the Trust Account of $142,997.

For the three months ended September 30, 2020, we had a net loss of $113,691, which consists of operating costs of $184,615, transaction costs associated with the Initial Public Offering of $671,901, and a provision for income taxes of $8,714, offset by the interest earned on marketable securities held in Trust Account of $96,143, unrealized gain on marketable securities held in Trust Account of $41,496, and changes in fair value of warrant liabilities of $613,900.

For the period from February 14, 2020 (inception) through September 30, 2020, we had a net loss of $114,691, which consists of formation and operational costs of $185,615, transaction costs associated with the Initial Public Offering of $671,901, and a provision for income taxes of $8,714, offset by the interest earned on marketable securities held in Trust Account of $96,143, unrealized gain on marketable securities held in Trust Account of $41,496, and changes in fair value of warrant liabilities of $613,900.

~~Liquidity and Capital Resources~~

On July 7, 2020, we consummated the Initial Public Offering of 27,600,000 Units at a price of $10.00 per Unit, which includes the full exercise by the underwriters of the over-allotment option to purchase an additional 3,600,000, generating gross proceeds of $276,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 7,520,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant in a private placement to our stockholders, generating gross proceeds of $7,520,000.

~~Table of Contents~~

Following the Initial Public Offering, the full exercise of the over-allotment option by the underwriters’ and the sale of the Private Placement Warrants, a total of $276,000,000 was placed in the Trust Account and we had $1,389,212 of cash held outside of the Trust Account, after payment of costs related to the Initial Public Offering, and available for working capital purposes. We incurred $15,851,828 in transaction costs, including $5,520,000 of underwriting fees, $9,660,000 of deferred underwriting fees and $671,828 of other offering costs.

For the nine months ended September 30, 2021, cash used in operating activities was $362,889. Net loss of $3,657,398 was affected by changes in fair value of warrant liabilities of $2,284,340, an unrealized gain on marketable securities held in Trust Account of $2,231, interest earned on marketable securities held in the Trust Account of $142,997 and changes in operating assets and liabilities, which provided $1,155,397 of cash from operating activities.

For the period from February 14, 2021 (inception) through September 30, 2020, cash used in operating activities was $212,209. Net loss of $680,079 was affected by changes in fair value of warrant liabilities of $48,512, an unrealized gain on marketable securities held in Trust Account of $41,496, interest earned on marketable securities held in the Trust Account of $96,143 and changes in operating assets and liabilities, which used $26,594 of cash from operating activities.

As of September 30, 2021, we had cash and marketable securities held in the Trust Account of $276,178,675. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account to complete our Business Combination. We may withdraw interest to pay franchise and income taxes. During the period ended September 30, 2021, we have withdrawn $176,006 of interest earned on the Trust Account for the payment of franchise taxes. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

As of September 30, 2021, we had cash of $304,944, respectively outside of the Trust Account. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination.

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we would repay such loaned amounts. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into warrants, at a price of $1.50 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants, including as to exercise price, exercisability and exercise period. The terms of such loans by our officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. The loans would be repaid upon consummation of a Business Combination, without interest.

On July 28, 2021, the Sponsor committed to provide the Company an aggregate of $4,000,000 in loans for working capital purposes. These loans will be non-interest bearing, unsecured and will be repaid upon the consummation of a business combination. If the Company does not consummate a business combination, all amounts loaned to the Company in connection with these loans will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. As a result, management has determined that sufficient capital exists to sustain operations through the earlier of the consummation of a Business Combination or July 7, 2022, the scheduled liquidation date of the Company if a Business Combination is not completed.

~~Off-Balance Sheet Arrangements~~

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2021. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

~~Table of Contents~~

~~Contractual obligations~~

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay an affiliate of the Sponsor a monthly fee of $10,000 for office space, utilities and secretarial and administrative support to the Company. We began incurring these fees on July 1, 2020 and will continue to ~~incur these fees monthly~~remain an “emerging growth company” until the ~~earlier~~earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of this registration; (2) the ~~Business Combination and the Company’s liquidation.~~

~~Critical Accounting Policies~~

~~The preparation of condensed consolidated financial statements and related disclosures~~fiscal year in ~~conformity with accounting principles generally accepted in the United States of America requires management~~which our total annual gross revenue is equal to ~~make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at~~or more than $1.07 billion; (3) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the condensed consolidated financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

~~Warrant Liabilities~~SEC.

We account for the Warrants in accordance with the guidance contained in ASC 815-40-15-7D and 7F under which the Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the Warrants as liabilities at their fair value and adjust the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statements of operations. The Private Placement Warrants and the Public Warrants for periods where no observable traded price was available are valued using a Monte Carlo simulation. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date.

~~Class A Common Stock Subject to Possible Redemption~~

We account for our shares of Class A common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, the Class A common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of our unaudited condensed consolidated balance sheets.

~~Net Income (Loss) per Common Share~~

Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common stock outstanding during the period. We apply the two-class method in calculating income (loss) per common share. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value.

~~Table of Contents~~

~~Recent accounting standards~~

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We adopted ASU 2020-06 on January 1, 2021. The adoption of ASU 2020-06 did not have an impact on our condensed consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our unaudited condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures ~~About~~about Market Risk

~~Not required for~~We are a smaller reporting ~~companies.~~company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and are not required to provide the information otherwise required under this item.

Item 4. Controls and ~~Procedures~~Procedures.

Previously Disclosed Material Weakness

As previously disclosed in Part II, Item 9A of our 2021 Annual Report, CPSR's management prior to the Business Combination concluded that CPSR’s management prior to Business Combination did not maintain effective internal control over financial reporting as of December 31, 2021, due to a material weakness related to CPSR's historical consolidated financial statements issued prior to the Business Combination. The material weakness related to CPSR prior to the Business Combination not having adequate controls over accounting for complex financial instruments associated with the accounting for warrants issued in connection with CPSR’s initial public offering.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended March 31, 2022, we completed the Business Combination, which resulted in a change in management responsible for the preparation and review of our consolidated financial statements. Effective as of the closing of the Business Combination, the management of Legacy Gelesis is responsible for internal control over financial reporting and the former management of CPSR no longer participates in financial reporting. Additionally, the internal controls of Legacy Gelesis became our internal controls.

Evaluation of Disclosure Controls and Procedures

~~Disclosure~~

We maintain “disclosure controls and ~~procedures~~procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed ~~by us~~ in ~~our~~the reports we file or submit under the Exchange Act ~~reports~~ is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and ~~forms,~~forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that ~~such~~ information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, ~~or persons performing similar functions,~~ as appropriate to allow timely decisions regarding required disclosure.

~~Under~~ In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the ~~supervision~~benefits of possible controls and procedures relative to their costs.

Subsequent to the Business Combination, our management, with the participation of our ~~management, including~~Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer and principal financial ~~and accounting~~ officer, ~~we conducted an evaluation of~~respectively, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. Our assessment is that, post-Business Combination, we have a sufficiently staffed and technically experienced finance and accounting team to address the ~~end~~financial reporting requirements of ~~the fiscal quarter ended September 30, 2021, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act.~~a public company. Based on ~~this~~such evaluation, our ~~principal executive officer~~Chief Executive Officer and ~~principal financial and accounting officer has~~Chief Financial Officer have concluded ~~that our disclosure controls and procedures were not effective, due solely to~~the conditions causing the material weakness no longer existed, and are not expected to exist. Accordingly, we determined the material weakness did not exist in ~~our~~ internal control over financial reporting ~~related to~~as of March 31, 2022. Management has concluded that the Company’s accounting for complex financial instruments. As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that thecondensed consolidated financial statements included in this ~~Form 10-Q~~Quarterly Report present fairly, in all material respects, ~~our~~the Company’s financial position, results of operations and cash flows for the ~~period presented.~~

Management has implemented remediation steps to improve our internal control over financial reporting. Specifically, we expanded and improved our review process for complex financial instruments and related accounting standards. We plan to further improve this process by enhancing access to accounting literature, identification of third-party professionalsperiods disclosed in accordance with ~~whom to consult regarding complex accounting applications and consideration of additional staff with the requisite experience and training to supplement existing accounting professionals.~~

~~Changes in Internal Control over Financial Reporting~~

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

U.S. GAAP.

2838

~~Table of Contents~~

PART ~~II -~~ II—OTHER INFORMATION

Item 1. Legal Proceedings.

~~None.~~

From time to time, we are party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of these matters could materially affect our future results of operations, cash flows, or financial position. We are not presently party to any legal proceedings that, in the opinion of management, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows.

Item 1A. Risk Factors.

Certain factors that may affect the Company’s business or operations are described under “Risk Factors” in Part I, Item 1A, of our 2021 Annual Report. Except as set forth below, there have ~~identified a~~been no material ~~weakness~~changes to our risk factors from those previously disclosed in our ~~internal control over financial reporting. This material weakness could continue to adversely affect~~2021 Annual Report.

An investment in our ~~ability to report our results~~securities involves a high degree of ~~operations~~risk. You should consider carefully all of the risks described below and ~~financial condition accurately and~~under “Risk Factors” in ~~a timely manner.~~

Our management is responsible for establishing and maintaining adequate internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our management is likewise required, on a quarterly basis, to evaluate the effectivenessPart I, Item 1A, of our internal controls and to disclose any changes and material weaknesses identified through such evaluation of those internal controls. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

~~As described elsewhere~~2021 Annual Report, together with the other information contained in this Quarterly Report ~~on Form 10-Q, we have identified a material weakness~~and in our ~~internal control over~~2021 Annual Report, before making a decision to invest in our securities. If any of the following events, or the events described under “Risk Factors” in Part I, Item 1A, of our 2021 Annual Report, occur, our business, financial ~~reporting related to the Company’s accounting for complex financial instruments. As a result of this material weakness, our management has concluded that our disclosure controls~~condition and procedures were not effective as of September 30, 2021. See “Note 2—Restatement of Previously Issued Financial Statements” to the accompanying financial statements, as well as Part I. Item 4. Controls and Procedures included in this Quarterly Report on Form 10-Q. We have taken a number of measures to remediate the material weaknesses described herein. However, if we are unable to remediate our material weaknesses in a timely manner or we identify additional material weaknesses, weoperating results may be unable to provide required financial information in a timely and reliable manner and we may incorrectly report financial information. Likewise, if our financial statements are not filed on a timely basis, we could be subject to sanctions or investigations by the stock exchange on which our shares of Class A common stock are listed, the SEC or other regulatory authorities. Failure to timely file will cause us to be ineligible to utilize short form registration statements on Form S-3 or Form S-4, which may impair our ability to obtain capital in a timely fashion to execute our business strategies of issue shares to effect an acquisition.materially adversely affected. In either case, there could result a material adverse effect on our business. The existence of material weaknesses or significant deficiencies in internal control over financial reporting could adversely affect our reputation or investor perceptions of us, which could have a negative effect onthat event, the trading price of our ~~stock.~~ securities could decline, and you could lose all or part of your investment.

The price of our common stock may be volatile, and you could lose all or part of your investment.

The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. For example, our stock traded within a range of a high price of $6.62 and a low price of $2.75 per share for the period of January 14, 2022, our first day of trading on the New York Stock Exchange through May 11, 2022. Factors which affect the volatility of the market price of our common stock include, without limitation:

•

any delay in our regulatory filings or any adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;

•

changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial requirements for approvals;

•

adverse developments concerning our manufacturers or its manufacturing plans;

•

our ability to generate sufficient patient demand for its product and product candidates;

•

our inability to establish collaborations, if needed;

•

our failure to commercialize its product candidates;

•

departures of key scientific, commercial or management personnel;

•

unanticipated serious safety concerns related to the use of our product candidates;

•

introduction of new products or services offered by us or our competitors;

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

•

our ability to effectively manage its growth;

•

actual or anticipated variations in quarterly operating results;

•

our cash position;

•

our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;

•

publication of research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts;

•

changes in the market valuations of similar companies;

•

overall performance of the equity markets;

•

sales of our common stock by us or our shareholders in the future;

•

trading volume of our common stock;

•

changes in accounting practices;

•

ineffectiveness of our internal controls;

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•

significant lawsuits, including patent or shareholder litigation;

•

general political and economic conditions; and

•

other events or factors, many of which are beyond our control.

In addition, the stock market in general, and the NYSE and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s attention and resources, which would harm our business, financial condition and results of operations.

Future sales and issuances of our common stock or rights to purchase our common stock, including pursuant to the Gelesis Holdings, Inc. 2021 Stock Option and Incentive Plan and future exercise of warrants or registration rights, could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall.

We expect that significant additional capital may be needed in the future to continue our planned operations, including expanding commercial operations, self-commercialization of our products in new markets, conducting clinical trials, expanded research and development activities, and costs associated with operating as a public company. To raise capital, we may sell shares of our common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell shares of our common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing shareholders, and new investors could gain rights, preferences, and privileges senior to existing holders of our common stock.

Sales of a substantial number of shares of our common stock in the public market, including the resale of the shares of common stock held by our stockholders, could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Of the 72,390,413 shares of our common stock outstanding as of May 11, 2022, approximately 42,668,860 and 4,917,221 shares are currently subject to restrictions on transfer under 180-day and 360-day lock-up under agreements, respectively, entered into between us and the holders of those shares. These restrictions are due to expire on July 13, 2022 and January 13, 2023, respectively, resulting in these shares becoming eligible for public sale on July 14, 2022 and January 14, 2023, respectively, if they are registered under the Securities Act of 1933, as amended (the “Securities Act”), or if they qualify for an exemption from registration under the Securities Act. Pursuant to our Amended and Restated Registration and Stockholder Rights Agreement, dated January 13, 2021, by and among the us and the stockholders party thereto (the “Registration Rights Agreement”), certain of our stockholders are entitled to registration rights requiring us to file a registration statement to register such securities for resale.

The registrable securities that we are obligated to register pursuant to our obligations under the Registration Rights Agreement and the Subscription Agreements with PIPE Investors would represent approximately 82.9% of the shares of our common stock currently outstanding as of the date of this Quarterly Report, including those issuable upon exercise of the warrants. After it is effective and until such time that it is no longer effective, the registration statement registering such registrable securities will ~~incur~~permit the resale of these shares. The resale, or expected or potential resale, of a substantial number of our common stock in the public market could adversely affect the market price for our common stock and make it more difficult for existing stockholders to sell their holdings at times and prices that they determine are appropriate. Furthermore, we expect that, because there will be a large number of shares registered pursuant to the registration statement we are required to file pursuant to the Registration Rights Agreement, the selling

securityholders thereunder will continue to offer the securities covered thereby for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to the registration statement may continue for an extended period of time.

We have also registered all shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock‑up agreements described above. If any of these additional ~~costs~~shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.

In addition, our common stock is also subject to ~~remediate material weaknesses~~potential dilution from the exercise of up to 24,333,365 warrants, the exercise of up to 15,144,811 stock options, the issuance of common stock pursuant to the vesting of up to 5,2727,601 restricted stock units, the issuance of up to 23,482,845 earnout shares pursuant to the triggering events in the Business Combination Agreement, and the potential issuance of common stock in connection with future equity and or convertible debt financings. Sales of substantial numbers of such shares in the public market, including the resale of the shares of common stock held by our ~~internal control over financial reporting,~~stockholders, could adversely affect the market price of our common stock, the impact of which is increased as ~~described in Part I. Item 4. Controls and Procedures. We~~the value of our stock price increases.

There can ~~give~~be no assurance that the ~~measures~~warrants will be in the money at the time they become exercisable; they may expire worthlessand therefore we will not receive cash proceeds from the exercise of warrants.

As of the date of this Quarterly Report, we have ~~taken~~13,800,000 outstanding Public Warrants to purchase 13,800,000 shares of our common stock, exercisable at an exercise price of $11.50 per share, which expire on the earlier to occur of January 13, 2027 or redemption; (ii) 7,520,000 outstanding Private Warrants to purchase 7,520,000 shares of our common stock, exercisable at an exercise price of $11.50 per share, which expire on the earlier to occur of January 13, 2027 or redemption and ~~plan~~(iii) 3,013,365 exercisable Rollover Warrants, 1,353,062 of which are exercisable at an exercise price of $4.26 and expire on October 21, 2030 and 1,660,303 of which are exercisable at an exercise price of $0.02 and expire on February 15, 2025.

The exercise of warrants is highly dependent on the price of our common stock and the spread between the exercise price of the warrant and the price of our common stock at the time of exercise. For example, to ~~take~~the extent that the price of our common stock exceeds $11.50 per share, it is more likely that holders of our Public Warrants and Private Warrants will exercise their warrants. To the extent that the price of our common stock is less than $11.50 per share, it is less likely that such holders will exercise their warrants. As of May 11, 2022, the price of our common stock price was $4.53 per share. There can be no assurance that our warrants will be in the ~~future will remediate the material weakness identified or that any additional material weaknesses or restatements of financial results will not arise~~money prior to their expiration. Our Public Warrants under certain conditions, as described in the warrant agreement, are redeemable by the Company at a price of $0.01 per warrant or on a cashless basis. Our Private Warrants are not redeemable so long as they are held by the initial stockholders and are exercisable on a cashless basis. Our Rollover Warrants are not redeemable and are exercisable on a cashless basis only with respect to the 1,660,303 warrants that have an exercise price of $0.02. As such, it is possible that we may never generate any cash proceeds from the exercise of our warrants.

The financial and operational projections and commercialization and product candidate development timelines that we may provide from time to time are subject to inherent risks.

The projections and timelines that our management may provide from time to time (including with respect to financial or operational matters, commercialization efforts or product candidate development) reflect numerous assumptions made by our management, including assumptions with respect to our specific as well as general business, economic, market and financial conditions, including our ability to raise additional financing, and other matters, all of which may be difficult to predict and many of which are beyond our control. Accordingly, there is a risk that the assumptions made in preparing the projections, or the projections themselves, will prove inaccurate or, in the event we do not successfully raise subsequent financing, that our commercialization or product development activities may be curtailed. There will be differences between actual and projected results, and actual results may be materially different from those contained in our projections or timelines. Further, if our commercialization or product development activities are slowed or stopped, we would be unable to meet the timelines and projections previously provided by us. The inclusion of projections or timelines in (or incorporated by reference in) this Quarterly Report or any other filing we make with the SEC should not be regarded as an indication that we or our management or representatives considered or consider such projections and timelines to be a reliable prediction of future events, and the projections and timelines should not be relied upon as such.

If certain holders of our common stock sell a significant portion of their securities, it may negatively impact the market price of the shares of our common stock and such holders still may receive significant proceeds.

As of the date of this Quarterly Report, the market price of our common stock is below $10.00 per share, which was the price per unit sold in the initial public offering of our predecessor, CPSR, the per-share price of the 9,000,000 shares of Class A Common Stock our predecessor sold to certain investors in connection with our Business Combination in a private placement for an aggregate amount of

$90.0 million (the “PIPE Financing”) and also the per share value of the consideration issued to Legacy Gelesis shareholders upon consummation of our Business Combination. However, certain of our shareholders who hold shares of our common stock that were (i) originally purchased by our predecessor’s sponsor, Capstar Sponsor Group, LLC, in a private placement prior to our predecessor’s initial public offering (the “Founder Shares”) or (ii) originally issued by CPSR in a private placement in connection with Backstop Agreement, dated December 30, 2021 (the “Backstop Agreement”), between CPSR and certain investors (the “Backstop Shares”), may nonetheless be willing to sell such Founder Shares or Backstop Shares as they were originally purchased at an effective price significantly less than $10.00 per share. The currently outstanding 4,916,250 Founder Shares were purchased at an effective price of $0.0051 per share. Holders of the Backstop Shares purchased an aggregate of 744,217 shares of CPSR’s Class A common stock in a private placement at a price of $10.00 per share, for an aggregate purchase price of $7.4 million and such holders also received an aggregate of 1,983,750 shares of CPSR Class A common stock as additional consideration, resulting in an effective purchase price for the currently outstanding 2,727,967 Backstop Shares of approximately $2.73 per share. Accordingly, holders of the Founder Shares and Backstop Shares could sell their securities at a per-share price that is less than $10.00 and still realize a significant profit from the sale of those securities that could not be realized by our other shareholders. On May 11, 2022, the closing price of our common stock was $4.53. Based on this closing price, the aggregate sales price of the Founder Shares would be approximately $22.3 million and the aggregate sales price of the Backstop would be approximately $12.4 million.

The Founder Shares and 1,983,750 of the Backstop Shares are currently subject to restrictions on transfer under applicable lock-up agreements; however, these restrictions are due to ~~a failure~~expire on July 13, 2022 and January 13, 2023, respectively, resulting in these shares becoming eligible for public sale on July 14, 2022 and January 14, 2023, respectively, if they are registered under the Securities Act, or if they qualify for an exemption from registration under the Securities Act. Pursuant to ~~implement and maintain adequate internal control over financial reporting or circumvention of these controls. In addition, even if we are successful in strengthening~~ our ~~controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation~~Registration Rights Agreement, certain of our ~~financial statements.~~stockholders, including holders of the Founder Shares and holders of the Backstop Shares, are entitled to registration rights requiring us to register such securities for resale.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

~~Private Placement~~

~~On July 7, 2020, simultaneous~~See Note 3, “Business Combination and Reverse Recapitalization,” in the accompanying Notes to unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report regarding Subscription Agreements between CPSR and certain investors and the Backstop Agreement between CPSR and certain investors.

As discussed in Note 3, “Business Combination and Reverse Recapitalization,” in the accompanying Notes to unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report, in connection with the ~~consummation~~Business Combination, pursuant to the Subscription Agreements, each dated July 19, 2021, the PIPE Investors purchased an aggregate of ~~the Initial Public Offering and~~9,000,000 shares of CPSR's Class A common stock in a private placement at a price of $10.00 per share for an aggregate purchase price of $90.0 million. The PIPE Investment was consummated on January 13, 2022 in connection with the closing of the ~~over-allotment option, we consummated~~Business Combination. In addition, pursuant to the ~~private placement of~~Backstop Agreement, dated December 30, 2021, the Backstop Investors purchased an aggregate of ~~7,520,000 warrants~~744,217 shares of CPSR's Class A common stock in a private placement at a price of ~~$1.00~~$10.00 per ~~Private Placement Warrant, generating total proceed~~share for an aggregate purchase price of ~~$7,520,000.~~$7.4 million. Additionally, CPSR issued the Backstop Investors 1,983,750 CPSR Class A common stock as additional consideration. The ~~issuance was made~~transactions contemplated by the Backstop Agreement were consummated on January 13, 2022 in connection with the closing of the Business Combination. The shares of Class A common stock issued pursuant to the Subscription Agreements and the Backstop Agreement have not been registered under the Securities Act in reliance upon the exemption ~~from registration contained~~provided in Section 4(a)(2) of the Securities Act.

The ~~Private Placement Warrants are identical~~Company intends to use the proceeds from the PIPE Investment and the sale of shares to the ~~warrants underlying~~Backstop Investors to support the ~~Units sold in the Initial Public Offering, except that the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion~~sale of ~~a Business Combination, subject to certain limited exceptions~~Plenity.
.

~~Table of Contents~~

~~Use of Proceeds from the Initial Public Offering~~

On July 7, 2020, we consummated the Initial Public Offering of 27,600,000 Units, which includes the full exercise by the underwriters of the over-allotment option to purchase an additional 3,600,000 Units. The Units sold in the Initial Public Offering were sold at an offering price of $10.00 per unit, generating total gross proceeds of $276,000,000. Citigroup Global Markets Inc., UBS Securities LLC and BTIG, LLC acted as joint book-running manager. The securities in the offering were registered under the Securities Act on a registration statement on Form S-1 (No. 333-239094 and 333-239630). The Securities and Exchange Commission declared the registration statement effective on July 1, 2020.

We paid a total of $5,520,000 in underwriting discounts and commissions and $671,828 for other offering costs related to the Initial Public Offering. In addition, the underwriters agreed to defer $9,660,000 in underwriting discounts and commissions.

Of the gross proceeds received from the Initial Public Offering, the closing of the over-allotment option and the Private Placement Warrants, $276,000,000 was placed in the Trust Account. The proceeds are held in the Trust Account located in the United States and shall be invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the funds in the Trust Account.

Item 3. Defaults Upon Senior Securities.

~~None.~~

None.

Item 4. Mine Safety Disclosures.

~~Not Applicable.~~

Not applicable.

Item 5. Other Information.

~~None.~~

Not applicable.

3043

~~Table of Contents~~

Item 6. ~~Exhibits~~Exhibits.

~~The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.~~


~~No.~~Exhibit Number		Description ~~of Exhibit~~
~~2.1~~31.1*		Business Combination Agreement, dated as of July 19, 2021, by and between Capstar Special Purpose Acquisition Corp, CPSR Gelesis Merger Sub, Inc. and Gelesis, Inc. (incorporated by reference to Exhibit 2.1 to Current Report on Form 8-K/A filed with the SEC on July 20, 2021.)
31.1*		Certification of Principal Executive Officer ~~and Principal Financial Officer~~ Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act ~~Rules 13a-14(a) and 15(d)-14(a),~~of 1934, as ~~adopted~~Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of ~~2002~~2002.
32.1*31.2		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Principal Executive Officer ~~and~~Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as ~~adopted~~Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of ~~2002~~2002.
101.INS*		~~XBRL Instance Document~~
101.CAL*101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*101.DEF		~~XBRL Taxonomy Extension Schema Document~~
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*101.LAB		Inline XBRL Taxonomy Extension ~~Labels~~Label Linkbase Document
101.PRE*101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*104		Cover Page Interactive Data File ~~(formatted as~~(embedded within the Inline XBRL ~~and contained in Exhibit 101)~~

*	~~Filed herewith.~~

**	~~Furnished.~~document)

~~Table of Contents~~* Filed herewith.

~~SIGNATURES~~

~~In accordance with~~44

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	~~CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.~~	Company Name

Date: ~~November 15, 2021~~May 12, 2022	~~By:~~	By:	/s/ ~~R. Steven Hicks~~Yishai Zohar
	~~Name:~~	~~R. Steven Hicks~~	Yishai Zohar
	~~Title:~~		Chief Executive Officer ~~and Chief Financial Officer~~ (Principal Executive Officer)
		(Principal Executive Officer and Principal Accounting and Financial Officer)
Date: May 12, 2022		By:	/s/ Elliot Maltz
			Elliot Maltz
			Chief Financial Officer (Principal Financial and Accounting Officer)


~~Delaware~~		~~84-4730610~~
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
501 Boylston Street, Suite 6102, Boston, MA	02116
(~~I.R.S. Employer~~Address of principal executive offices)	~~Identification No.)~~ (Zip Code)


Title of each class	Trading Symbol(s)		Name of each exchange on which registered
~~Units, each consisting of one share of Class A Common Stock and one-half of one Warrant~~	~~CPSR.U~~		~~The New York Stock Exchange~~
~~Class A~~ Common ~~Stock,~~stock, par value $0.0001 per share	~~CPSR~~	GLS	~~The~~	New York Stock Exchange
~~Warrants,~~Redeemable warrants, each whole warrant exercisable for one share of ~~Class A~~ Common Stock at an exercise price of $11.50	~~CPSR WS~~	GLS WS	~~The~~	New York Stock Exchange


Large accelerated filer	☐ ~~Large accelerated~~		Accelerated filer	☐~~Accelerated filer~~
Non-accelerated filer	☒ ~~Non-accelerated filer~~	☒	Smaller reporting company
	☒
			Emerging growth company	☒


	September 30,		December 31,
	2021		2020
	(Unaudited)		(Restated)
ASSETS
Current assets
Cash	$	304,944	$	491,827
Prepaid expenses		39,816		65,973
Total Current Assets		344,760		557,800

Cash and marketable securities held in Trust Account		276,178,675		276,209,453
Total Assets	$	276,523,435		276,767,253

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities - Accounts payable and accrued expenses	$	2,760,072		1,630,832
Warrant liabilities		32,386,148		30,101,808
Deferred underwriting fee payable		9,660,000		9,660,000
Total Liabilities		44,806,220		41,392,640

Commitments

Class A common stock subject to possible redemption 27,600,000 shares at redemption value as of September 30, 2021 and December 31, 2020		276,028,675		276,033,447

Stockholders’ Deficit
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; NaN issued and outstanding		0		0
Class A common stock, $0.0001 par value; 100,000,000 shares authorized, 0 shares issued and outstanding (excluding 27,600,000 shares subject to possible redemption) at September 30, 2021 and December 31, 2020		0		0
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 6,900,000 shares issued and outstanding at September 30, 2021 and December 31, 2020		690		690
Additional paid-in capital		0		0
Accumulated deficit		(44,312,150)		(40,659,524)
Total Stockholders’ Deficit		(44,311,460)		(40,658,834)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	276,523,435		276,767,253


							For the
							Period from
							February 14,
							2020
	Three Months		Nine Months		Three Months		(Inception)
	Ended		Ended		Ended		Through
	September 30,		September 30,		September 30,		September 30,
	2021		2021		2020		2020
General and administrative expenses	$	1,113,342	$	1,518,286	$	184,615	$	185,615
Loss from operations		(1,113,342)		(1,518,286)		(184,615)		(185,615)

Other income (expense):
Interest earned on marketable securities held in Trust Account		138,117		142,997		96,143		96,143
Unrealized gain (loss) on marketable securities held in Trust Account		(106,039)		2,231		41,496		41,496
Change in fair value of warrant liabilities		(13,174,144)		(2,284,340)		613,900		613,900
Transaction costs associated with the Initial Public Offering		0		0		(671,901)		(671,901)
Total other income (expense), net		(13,142,066)		(2,139,112)		79,638		79,638

Loss before income taxes		(14,255,408)		(3,657,398)		(104,977)		(105,977)
Provision for income taxes		0		0		(8,714)		(8,714)
Net loss	$	(14,255,408)	$	(3,657,398)	$	(113,691)	$	(114,691)

Basic and diluted weighted average shares outstanding, Class A common stock		27,600,000		27,600,000		25,780,220		10,761,468

Basic and diluted net loss per share, Class A common stock	$	(0.41)	$	(0.11)	$	(0.00)	$	(0.01)

Basic and diluted weighted average shares outstanding, Class B common stock		6,900,000		6,900,000	$	6,840,659		6,350,917

Basic and diluted net loss per share, Class B common stock	$	(0.41)	$	(0.11)	$	(0.00)	$	(0.01)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


~~Capstar Special Purpose Acquisition Corp.~~Delaware	84-4730610
(~~Exact name of registrant as specified in its charter)~~


		~~Page~~
~~PART 1 – FINANCIAL INFORMATION~~		Page

~~Item 1.~~	~~Condensed Consolidated Financial Statements~~

PART I.	~~Condensed Consolidated Balance Sheets as of September 30, 2021(Unaudited) and December 31, 2020~~FINANCIAL INFORMATION	1
Item 1.	Financial Statements	1
	Unaudited Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021	1
	Unaudited Condensed Consolidated Statements of Operations for the three months ended ~~September 30,~~March 31, 2022 and 2021 ~~and 2020, for the nine months ended September 30, 2021, and for the period from February 14, 2020 (inception) through September 30, 2020~~ ~~(Unaudited)~~	2

	Unaudited Condensed Consolidated Statements of ~~Changes in Stockholders’ (Deficit) Equity~~Comprehensive Loss for the three months ended ~~September 30,~~March 31, 2022 and 2021 ~~and 2020, for the nine months ended September 30, 2021, and for the period from February 14, 2020 (inception) to September 30, 2020 (Unaudited)~~	3
	Unaudited Condensed Consolidated Statements of Noncontrolling Interest, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months ended March 31, 2022 and 2021	4
	Unaudited Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and 2021 ~~and for the period from February 14, 2020 (inception) to September 30, 2020 (Unaudited)~~	5

	Notes to Unaudited Condensed Consolidated Financial Statements ~~(Unaudited)~~	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2426

Item 3.	Quantitative and Qualitative Disclosures ~~about~~About Market Risk	2838

Item 4.	~~Control~~Controls and Procedures	2838
PART II.
~~PART II –~~ OTHER INFORMATION		2939

Item 1.	Legal Proceedings	2939

Item 1A.	Risk Factors	2939

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2943

Item 3.	Defaults Upon Senior Securities	3043

Item 4.	Mine Safety Disclosures	3043

Item 5.	Other Information	3043

Item 6.	Exhibits	31
		44
SIGNATURES		3245


	Class A			Class B			Additional				Total
	Common Stock			Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Deficit
Balance - January 1, 2021, as restated	—	$	—	6,900,000	$	690	$	0	$	(40,659,524)	$	(40,658,834)

Accretion for Class A common stock to redemption amount	—		—	—		—		0		(54,865)		(54,865)

Net income	—		—	—		—		0		14,686,984		14,686,984

Balance - March 31, 2021	—	$	—	6,900,000	$	690	$	0	$	(26,027,405)	$	(26,026,715)

Accretion for Class A common stock to redemption amount	—		—	—		—		0		41,715		41,715
Net loss	—		—	—		—		0		(4,088,974)		(4,088,974)
Balance - June 30, 2021	—	$	—	6,900,000	$	690	$	0	$	(30,074,664)	$	(30,073,974)
Accretion for Class A common stock to redemption amount	—		—	—		—		0		17,922		17,922
Net loss	—		—	—		—		0		(14,255,408)		(14,255,408)
Balance – September 30, 2021	—	$	—	6,900,000	$	690	$	0	$	(44,312,150)	$	(44,311,460)


			For the period
			from February
			14, 2020
	Nine months		(Inception)
	ended September 30,		through September 30,
	2021		2020
Cash Flows from Operating Activities:
Net loss	$	(3,657,398)	$	(114,691)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account		(142,997)		(96,143)
Unrealized gain on marketable securities held in Trust Account		(2,231)		(41,496)
Transaction costs associated with the Initial Public Offering		0		671,901
Change in fair value of warrant liabilities		2,284,340		(613,900)
Deferred tax provision		0		8,714
Changes in operating assets and liabilities:
Prepaid expenses		26,157		(81,365)
Accounts payable and accrued expenses		1,129,240		54,771
Net cash used in operating activities		(362,889)		(212,209)

Cash Flows from Investing Activities:
Cash withdrawn from Trust Account to pay for franchise taxes		176,006		0
Investment of cash into Trust Account		0		(276,000,000)
Net cash provided by (used in) investing activities		176,006		(276,000,000)

Cash Flows from Financing Activities:
Proceeds from issuance of Class B common stock to Sponsor		0		25,000
Proceeds from sale of Units, net of underwriting discounts paid		0		270,480,000
Proceeds from sale of Private Placement Warrants		0		7,520,000
Proceeds from promissory note - related party		0		150,000
Repayment of promissory note - related party		0		(150,000)
Payment of offering costs		0		(671,828)
Net cash provided by financing activities		0		277,353,172

Net Change in Cash		(186,883)		1,140,963
Cash - Beginning of period		491,827		0
Cash - End of period	$	304,944	$	1,140,963
Non-Cash investing and financing activities:
Initial classification of Class A common stock subject to possible redemption	$	0	$	276,000,000
Change in value of Class A common stock subject to possible redemption	$	(4,772)	$	87,639
Deferred underwriting fee payable	$	0	$	9,660,000


	As Previously
	Reported		Adjustment		As Restated
Balance Sheet as of July 7, 2020
Class A common stock subject to possible redemption	$	244,996,570	$	31,003,430	$	276,000,000
Class A common stock	$	310	$	(310)	$	—
Additional paid-in capital	$	5,671,903	$	(5,671,903)	$	—
Accumulated deficit	$	(672,901)	$	(25,331,217)	$	(26,004,118)
Total stockholders’ equity (deficit)	$	5,000,002	$	(31,003,430)	$	(26,003,428)
Number of shares subject to redemption		24,499,657		3,100,343		27,600,000

Balance Sheet as of September 30, 2020
Class A common stock subject to possible redemption	$	245,554,779	$	30,532,860	$	276,087,639
Class A common stock	$	305	$	(305)	$	—
Additional paid-in capital	$	5,113,699	$	(5,113,699)	$	—
Accumulated deficit	$	(114,691)	$	(25,418,856)	$	(25,533,547)
Total stockholders’ equity (deficit)	$	5,000,003	$	(30,532,860)	$	(25,532,857)
Number of shares subject to redemption		24,547,683		3,052,317		27,600,000

Balance Sheet as of December 31, 2020
Class A common stock subject to possible redemption	$	230,374,604	$	45,658,843	$	276,033,447
Class A common stock	$	457	$	(457)	$	—
Additional paid-in capital	$	20,293,722	$	(20,293,722)	$	—
Accumulated deficit	$	(15,294,860)	$	(25,364,664)	$	(40,659,524)
Total stockholders’ equity (deficit)	$	5,000,009	$	(45,658,843)	$	(40,658,834)
Number of shares subject to redemption		23,034,669		4,565,331		27,600,000

Balance Sheet as of March 31, 2021
Class A common stock subject to possible redemption	$	245,061,587	$	31,026,725	$	276,088,312
Class A common stock	$	311	$	(311)	$	—
Additional paid-in capital	$	5,606,885	$	(5,606,885)	$	—
Accumulated deficit	$	(607,876)	$	(25,419,529)	$	(26,027,405)
Total stockholders’ equity (deficit)	$	5,000,010	$	(31,026,725)	$	(26,026,715)
Number of shares subject to redemption		24,493,884		3,106,116		27,600,000

Balance Sheet as of June 30, 2021
Class A common stock subject to possible redemption	$	240,972,620	$	35,073,977	$	276,046,597
Class A common stock	$	352	$	(352)	$	—
Additional paid-in capital	$	9,695,811	$	(9,695,811)	$	—
Accumulated deficit	$	(4,696,850)	$	(25,377,814)	$	(30,074,664)
Total stockholders’ equity (deficit)	$	5,000,003	$	(35,073,977)	$	(30,073,974)
Number of shares subject to redemption		24,084,470		3,515,530		27,600,000

Statement of Operations for the Period from February 14, 2020 (Inception) Through September 30, 2020
Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption		24,499,657		(24,499,657)		—
Basic and diluted weighted average shares outstanding, Non-redeemable common stock		7,559,767		(7,559,767)		—
Basic and diluted net loss per share, Non-redeemable common stock	$	(0.02)	$	0.02	$	—
Weighted average shares outstanding of Class A common stock		—		10,761,468		10,761,468
Basic and diluted net loss per share, Class A common stock	$	—	$	(0.01)	$	(0.01)
Weighted average shares outstanding of Class B common stock		—		6,350,917		6,350,917
Basic and diluted net loss per share, Class B common stock	$	—	$	(0.01)	$	(0.01)

Statement of Operations for the Period from February 14, 2020 (Inception) Through December 31, 2020
Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption		24,524,620		(24,524,620)		—
Basic and diluted weighted average shares outstanding, Non-redeemable common stock		8,269,814		(8,269,814)		—
Basic and diluted net loss per share, Non-redeemable common stock	$	(1.85)	$	1.85	$	—
Weighted average shares outstanding of Class A common stock		—		15,758,710		15,758,710
Basic and diluted net loss per share, Class A common stock	$	—	$	(0.69)	$	—
Weighted average shares outstanding of Class B common stock		—		6,513,871		6,513,871
Basic and diluted net loss per share, Class B common stock	$	—	$	(0.69)	$	(0.69)

Statement of Operations for the Three Months Ended March 31, 2021
Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption		23,034,669		(23,034,669)		—
Basic and diluted weighted average shares outstanding, Non-redeemable common stock		11,465,331		(11,465,331)		—
Basic and diluted net income per share, Non-redeemable common stock	$	1.28	$	(1.28)	$	—
Weighted average shares outstanding of Class A common stock		—		27,600,000		27,600,000
Basic and diluted net income per share, Class A common stock	$	—	$	0.43	$	0.43
Weighted average shares outstanding of Class B common stock		—		6,900,000		6,900,000
Basic and diluted net income per share, Class B common stock	$	—	$	0.43	$	0.43


Gross proceeds	$	276,000,000
Less:
Proceeds allocated to Public Warrants		(11,454,000)
Ordinary shares issuance costs		(15,179,714)
Plus:
Accretion of carrying value to redemption value		26,667,374

Ordinary shares subject to possible redemption, 12/31/20		276,033,447
Accretion of carrying value to redemption value		(4,772)
Ordinary shares subject to possible redemption, 9/30/21	$	276,028,675


													For the Period from
	Three Months Ended				Nine Months Ended				Three Months Ended				February 14,
	September 30,				September 30,				September 30,				2020 (Inception) Through
	2021				2021				2020				September 30, 2020
	Class A		Class B		Class A		Class B		Class A		Class B		Class A		Class B
Basic and diluted net income (loss) per common share
Numerator:
Allocation of net income (loss), as adjusted	$	(11,404,326)	$	(2,851,082)	$	(89,850)	$	(23,841)	$	(2,925,918)	$	(731,480)	$	(72,126)	$	(42,565)
Denominator:
Basic and diluted weighted average stock outstanding		27,600,000		6,900,000		25,780,220		6,840,659		27,600,000		6,900,000		10,761,468		6,350,917
Basic and diluted net income (loss) per common share	$	(0.41)	$	(0.41)	$	(0.00)	$	(0.00)	$	(0.11)	$	(0.11)	$	(0.01)	$	(0.01)


	Number of Options			Weighted- Average Exercise Price per Share			Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2021		4,889,820		$	10.39			6.17	$	54,449
Retroactive application of reverse recapitalization		7,784,666			(6.38	)
Adjusted and Outstanding at December 31, 2021		12,674,486		$	4.01			6.17	$	54,449
Granted		2,542,685
Exercised		—
Forfeited - unvested		(17,281	)	$	5.56
Forfeited - vested		(55,079	)	$	4.11
Expired		—
Outstanding at March 31, 2022		15,144,811		$	3.89			6.58	$	13,187
Exercisable at March 31, 2022		9,923,454		$	3.58			5.14	$	-
Vested and expected to vest at March 31, 2022		15,144,811		$	3.89			6.58	$	13,187


	Three Months Ended March 31,
	2022
Market price of common stock	$	3.33
Expected volatility		72.6	%
Expected term (in years)		6.1
Risk-free interest rate		1.7	%
Expected dividend yield		0.0	%


	Number of RSUs		Weighted- Average Grant Date Fair Value
Outstanding and Unvested at December 31, 2021		313,354	$	21.41
Retroactive application of reverse recapitalization		498,868	$	(13.15	)
Adjusted and Outstanding and Unvested at December 31, 2021		812,222	$	8.26
Granted		4,460,379	$	3.45
Vested		—
Forfeited		—
Outstanding and Unvested at March 31, 2022		5,272,601	$	4.19


	At March 31, 2022
Remaining 2022 maturities	$	474
2023		636
2024		555
2025		385
2026		32
More than 5 years		16
Total undiscounted lease maturities	$	2,098
Imputed interest		(176	)
Total lease liability	$	1,922


Description	Level	September 30, 2021		December 31, 2020
Assets:
Cash and marketable securities held in Trust Account	1	$	276,178,675	$	276,209,453

Liabilities:
Warrant Liability – Public Warrants	1	$	12,006,000	$	19,458,000
Warrant Liability – Private Placement Warrants	3	$	20,380,148	$	10,643,808


	September 30,			December 31,
	2021			2020
Risk-free interest rate		1.02	%		0.47	%
Expected Term		5.25			5.76
Dividend yield		0.00	%		0.00	%
Expected volatility		13.5	%		19.0	%
Exercise price	$	11.50		$	11.50
Unit Price	$	9.92		$	10.15


	Private Placement
Fair value as of December 31, 2020	$	10,643,808
Change in fair value		(5,273,024)
Fair value as of March 31, 2021		5,370,784
Change in fair value		1,422,600
Fair value as of June 30, 2021		6,793,384
Change in fair value		13,586,764
Fair value as of September 30, 2021		20,380,148